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ABSTRACT
Examining the Associative Learning and Accumbal Dopaminergic Mechanisms of Caffeine
Reinforcement
by
Curtis A. Bradley
Caffeine is the most consumed psychoactive substance in the world, and most caffeine
consumption in coffee and energy drinks is intended to produce a psychoactive effect. However,
caffeine is not a primary reinforcer in preclinical paradigms – non-human species do not reliably
take the drug to produce a psychoactive effect. However, caffeine is a ‘reinforcement enhancer’
in preclinical models; the effects of caffeine increase the motivation to obtain other non-drug
reinforcers. The overall goal of this project was to determine if these reinforcement enhancing
effects of caffeine could promote caffeine self-administration and to subsequently investigate the
behavioral and neurochemical underpinnings of this effect. We hypothesized reliable caffeine
self-administration would occur by adventitious pairing of caffeine with saccharin, a primary
reinforcer. Second, we hypothesized that caffeine enhances reinforcement by increasing the
salience of incentive stimuli, which are stimuli that come to evoke approach behaviors through
associative learning (e.g., Pavlovian conditioning). Finally, incentive salience is moderated by
dopamine release in the nucleus accumbens (NAc), an area highly involved in reward-learning
and substance dependence. Therefore, we hypothesized that if caffeine enhanced control of
approach behavior by incentives, then it would increase the ability of incentive stimuli to evoke
dopamine in the NAc. These studies show that intravenous delivery of caffeine with oral
saccharin increases operant relative to control groups responding for intravenous caffeine or oral
2

saccharin. The effect was also dose-dependent, confirming that the psychoactive effects of
caffeine increased behavior. We also extended this effect to an oral model of caffeine selfadministration, which included a simple sweetener (saccharin) or a complex oral vehicle
(saccharin with decaffeinated coffee) to mask the bitter taste of caffeine. Presenting caffeine with
oral saccharin promoted self-administration, relative to saccharin alone and did not depend on
the nature of the complexity of the vehicle. Caffeine also dose-dependently increased approach
to an incentive stimulus and this effect was associated with increased extracellular dopamine in
the NAc. These findings suggest caffeine enhances incentive motivation and that this effect may
result from increases in CS-evoked striatal dopamine.
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CHAPTER 1
INTRODUCTION
Human Caffeine Use
Caffeine Consumption
Caffeine is often described as the most consumed psychoactive substance in the world
(Glade, 2010). As of 2010, the United States Food and Drug Administration (FDA) estimates
that persons 2 years or older consume 131.9 mg/day on average (Somogyi, 2010). In the United
States, consumption of caffeinated soft drinks alone has increased from 11 gallons/year to 49
gallons/year per person over the past fifty years (Frary, Johnson, & Wang, 2005; Somogyi,
2010). Although caffeine is most often consumed via caffeinated beverages such as coffee and
soft drinks, the market for caffeine-infused products has grown substantially in recent years
(Frary et al., 2005; Somogyi, 2010). For example, caffeine can be consumed in a wide variety of
products such as energy drinks, alcoholic beverages, waffles, gum, sweets, and smokeless
tobacco. Possibly potentiating caffeine consumption, caffeine infused products are becoming a
growing public health concern as noted by multiple investigations by the FDA (FDA, 2010,
2015).
Caffeine Use Disorder
Currently recognized by the American Psychiatric Association (APA) as a condition for
further study, Caffeine Use Disorder (CUD) and Caffeine Dependence Syndrome (CDS) has
become a growing concern in the United States and is recognized by the World Health
Organization (WHO, 1992). In The International Statistical Classification of Diseases and
Related Health Problems (ICD-10), the WHO defines CDS as behavioral, cognitive, and
11

physiological symptoms that develop after repeated caffeine use (WHO, 1992). These symptoms
include drug craving, an inability to control drug use, persistence despite maladaptive health
consequences, increased tolerance, decreased priority of social responsibilities, and withdrawal
after periods of cessation (WHO, 1992). The APA recognizes diagnostic symptoms found in the
ICD-10 for CUD but requires the three clinical indicators of substance dependence to achieve
diagnosis: Persistent use despite unsuccessful quit attempts, continued caffeine use despite
negative physical and mental health consequences, and caffeine withdrawal or avoidance of
withdrawal via caffeine ingestion (APA, 2013).
Prevalence. A survey conducted in the United States estimated 9% of the population
meets diagnostic criteria for CUD (Hughes, Oliveto, Liguori, Carpenter, & Howard, 1998) and a
study conducted in Italy estimated prevalence rates closer to 6% (Ciapparelli et al., 2010;
Hughes, Oliveto, et al., 1998). A 6-9% prevalence rate would make CUD one of the top three
substance abuse disorders in America according to the DSM 5; behind Tobacco Use Disorder
(13%) and approximately equivalent to Alcohol Use Disorder (8.5%) (APA, 2013). In addition,
rates of CUD are highest among clinical populations. Individuals who have been diagnosed with
mood disorders, anxiety disorders, schizophrenia, or eating disorder have a 17% prevalence of
CUD (Ciapparelli et al., 2010; Hughes, McHugh, & Holtzman, 1998). Furthermore, comorbidity
of CUD is highest amongst individuals who regularly use illicit substances (20%) (Striley,
Griffiths, & Cottler, 2011). This may be caused by caffeine's ability to sensitize a person to the
effects of other drugs, such as cocaine, as seen in preclinical work (Green & Schenk, 2002;
Horger, Wellman, Morien, Davies, & Schenk, 1991). Caffeine Use Disorder, together with the
staggering demographics of public caffeine consumption, suggests caffeine may be a public
health concern that warrants further study. A thorough understanding of the effects of caffeine on
12

the brain and behavior is needed to understand the factors influencing the prevalence of caffeine
use and why this might be a concern for public health. For example, there is some debate about
whether the pharmacological effects of caffeine are reinforcing, whether caffeine influences
reward learning, and what effects caffeine has on the brain's ‘final common pathway’ for
substance use disorders: the mesolimbic dopamine system.
Caffeine Reinforcement in Humans
In congruence with survey data of caffeine consumption and maladaptive psychological
conditions caused by unhealthy caffeine consumption, caffeine functions as a negative reinforcer
in human subjects (Griffiths & Chausmer, 2000; Schuh & Griffiths, 1997). Drugs are considered
to be negatively reinforcing when they are self-administered in order to escape or avoid the
negative consequences of abstinence (i.e., a withdrawal syndrome; Markou, 1999). The negative
reinforcement perspective of caffeine offers the strongest support for the need to label caffeine as
a drug of abuse. For example, caffeine functions as a negative reinforcer in participants with
histories of moderate-to-high caffeine consumption (Griffiths, Bigelow, & Liebson, 1989).
Participants who blindly consume caffeinated coffee report decreases in withdrawal symptoms
and simultaneous increase in subjective liking when compared to consumption of decaffeinated
coffee (Griffiths, Bigelow, & Liebson, 1986). Additionally, moderate caffeine users who were
currently abstinent and experiencing withdrawal symptoms were willing to pay to avoid
ingesting a placebo or pay for a caffeine pill (Griffiths et al., 1989).
A negative reinforcement perspective of caffeine use still does not explain acute episodes
of consumption, the acquisition of chronic caffeine use leading to unhealthy caffeine
consumption, or relapse of caffeine use after the abstinence syndrome have abated (Griffiths &
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Woodson, 1988). On the other hand, human models of caffeine use via positive reinforcement
produce findings which are incongruent with the prevalence of public caffeine use. Consistent
caffeine self-administration only occurs in certain subsets of participants (Griffiths & Woodson,
1988). Conversely, participants prefer caffeine over placebo in the absence of symptoms
associated with caffeine withdrawal (Griffiths et al., 1989). More specifically, participants prefer
caffeinated coffee or capsules after two weeks of caffeine cessation. Caffeinated coffee and
capsules maintain higher rates of self-administration compared to decaffeinated coffee and
placebo capsules (Griffiths et al., 1989). Taken together, a strictly negative reinforcement
viewpoint of caffeine use does not offer a comprehensive explanation of caffeine use among
research with human subjects. Yet, clinical and preclinical models of caffeine self-administration
via positive reinforcement are weak and incongruous with caffeine consumption by the general
population. A deeper look into preclinical and clinical caffeine research is warranted to
understand the incongruous research findings and patterns of public caffeine consumption.
Preclinical Caffeine Research
Caffeine Self-Administration in Non-Human Subjects
Preclinical self-administration paradigms are considered the gold-standard in drug abuse
research (Le Foll & Goldberg, 2009). These procedures determine if a drug is a primary
reinforcer by observing whether an animal will work to self-administer a drug. If an animal
continuously works to receive the drug, it is reasonable to assume a psychoactive property of the
drug is perceived as pleasant. The pleasant, or rewarding, effect increases the probability of
future instances of the operant behavior contingent upon future infusions of the drug. Although
caffeine functions as a primary reinforcer in human participants and over 90% of the human
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population consumes the drug regularly (Evans, Critchfield, & Griffiths, 1994; Garrett &
Griffiths, 1998), studies with non-human animals provide little to no evidence of abuse liability
(see Griffiths & Woodson, 1988 for review). Intravenous caffeine self-administration has been
described as erratic (Deneau, Yanagita, & Seevers, 1969; Griffiths, Brady, & Bradford, 1979),
inconsistent (Atkinson & Enslen, 1976; Schuster, Fischman, & Johanson, 1981), and nonexistent (Collins, Weeks, Cooper, Good, & Russell, 1984; Hoffmeister & Wuttke, 1973).
Additionally, route of administration does not appear to influence caffeine consumption. Oral
caffeine self-administration, a more ecologically valid model of caffeine consumption, results in
weak and incongruent findings for a preclinical model of caffeine abuse liability (Heppner,
Kemble, & Cox, 1986; Vitiello & Woods, 1975). Preference for oral caffeine occurs at such low
concentrations that above-threshold doses are unobtainable unless a forced consumption
paradigm is administered prior to a free choice task (Heppner et al., 1986; Vitiello & Woods,
1975). Furthermore, caffeine self-administration does not appear to be species-specific. Rodent
and primate models are unsuccessful in establishing or maintaining intravenous caffeine selfadministration (see Griffiths & Woodson, 1988 for review). Interpretation of these results can be
complicated due to animals' exposure history to other drugs of abuse (Griffiths et al., 1979;
Hoffmeister & Wuttke, 1973; Schuster et al., 1981).
Associative Learning and Caffeine
The stark contrast between caffeine's low abuse liability in preclinical research and high
rates of drug use in the general population suggests a primary reinforcing effect of caffeine is not
enough to explain the prevalence of public caffeine consumption. Research outside of the selfadministration literature suggests caffeine’s effect on associative learning processes may
contribute to high rates of caffeine use. Conditioned Place Preference (CPP) is a model used by
15

preclinical researchers to determine drug abuse liability. In this associative learning paradigm, an
environment is repeatedly paired with a psychoactive dose of a drug. If the drug produces some
preferred internal state, often labeled euphoria, the environment will inherit some of the drug's
conditioned properties. As a result, animals prefer the environment associated with the drug in
comparison to a similar context associated with placebo/saline. Common drugs of abuse elicit
CPP and verify the model as a preclinical indicator of abuse liability (Tzschentke 2007 for
review). Caffeine induced CPP supports the idea that the stimulant has potential for abuse.
Caffeine induces CPP in rodents in a biphasic manner (Brockwell, Eikelboom, & Beninger,
1991; Hsu, Chen, Wang, & Chiu, 2009; Patkina & Zvartau, 1998). In other words, low to
moderate doses of caffeine induce CPP while higher doses reduce the time spent in the
environment paired with caffeine. Also, Hsu and colleagues (2009) discovered caffeine and the
adenosine A2A antagonist SCH 28261 induced CPP, while a selective adenosine A1 antagonist
had no effect on place preference (Hsu et al., 2009). Taken together, these findings implicate
caffeine's ability to alter reward perception which may occur via adenosine A2A receptor
antagonism and the resulting dopamine D2 receptor activation.
Parallels of Caffeine and Nicotine
Although preclinical models show effective caffeine-conditioned reward via CPP, this
preference for the drug-paired environment is small relative to more typical drugs of abuse such
as cocaine (Bedingfield, King, & Holloway, 1998). This pattern is reminiscent of another
psychomotor stimulant that is widely consumed by humans yet has relatively small reinforcing
and rewarding effects in preclinical models - nicotine. For example, caffeine- and nicotineinduced CPP has been best observed in the biased design (Bedingfield et al., 1998; Brielmaier,
McDonald, & Smith, 2008; Le Foll & Goldberg, 2005; Patkina & Zvartau, 1998). ‘Biased’ CPP
16

designs involve pre-tests in which rats are placed in an apparatus with free access to two distinct
environments, and the unconditioned preference between environments (i.e., based on time spent
in each side) can be measured. During conditioning, the subjects are repeatedly confined to each
environment and drug injections are paired with the initially non-preferred side; placebo
injections are paired with the preferred side. A shift in preference toward the non-preferred side
provides a more sensitive measure of conditioned reward, if interpretive pitfalls are accounted
for (e.g., a placebo-only group to account for spontaneous changes in side preference over time).
Weak to moderately rewarding drugs would be expected to confer weak conditioned rewarding
properties on the drug-paired environment and weaker observed preferences. Conditioned place
preference exclusive to biased designs indicate both drugs have weak subjective rewarding
effects in rodents, which lends further support for the weak subjective rewarding effects of the
drugs observed in humans (Griffiths & Woodson, 1988; Tzschentke, 2007). However, nicotine
and caffeine elicit higher rates of CPP when the drug-associated environment is paired with a
second reward. For example, nicotine CPP is more robust when the environment contains social
stimulus (Thiel, Sanabria, & Neisewander, 2009), cocaine (Buffalari et al., 2014), or sucrose
(Buffalari et al., 2014). Similarly, stronger rates of caffeine-induced CPP occur when the
environment is paired with cocaine injections (Bedingfield et al., 1998). Taken together,
caffeine and nicotine appear to induce weak levels of CPP that are enhanced by co-presentation
with rewarding stimuli.
In addition to CPP, nicotine and caffeine have similar effects in other preclinical models
of drug- and non-drug reinforcement. Like caffeine, nicotine is a weak primary reinforcer but
enhances responding for other rewards (Le Foll & Goldberg, 2009; Sheppard, Gross, Pavelka,
Hall, & Palmatier, 2012). For example, nicotine injections support low levels of operant behavior
17

when they are presented alone, but robustly increase responding for a reinforcing visual stimulus
(Donny et al., 2003). Early nicotine self-administration research revealed the importance of cue
lights associated with nicotine delivery in maintaining significant and consistent levels of selfadministration (Goldberg, Spealman, & Goldberg, 1981). This phenomenon was replicated in
later studies (Caggiula et al., 2001), confirming that intravenous delivery of nicotine alone was
insufficient to explain nicotine use and dependence. The relationship between nicotine,
rewarding stimuli, and self-administration was clarified by Donny and colleagues (2003). First,
nicotine enhanced responding for a rewarding stimulus regardless of the contingency for nicotine
delivery. Second, responding for a rewarding stimulus was attenuated and reestablished when
nicotine was removed and subsequently reinstated. Third, rates of nicotine self-administration
were low when delivered alone and significantly higher when paired with a rewarding stimulus.
Put together, these results confirm that nicotine functions as a weak primary reinforcer,
potentiates the efficacy of other reinforcers, and promotes high rates of self-administration
through co-presentation with other reinforcers.
Behavioral Mechanisms of the Reinforcement Enhancing Effects of Nicotine
Donny and colleagues (Donny et al., 2003) interpretation of increased responding for
rewards as reinforcement enhancement was challenged as ‘rate dependent’ increases based on
the behavioral activation commonly observed in psychostimulants (Frenk & Dar, 2004). Since
this criticism, nicotine's ability to increase operant responding for a reinforcer has been replicated
and observed with diverse primary reinforcers as well as conditioned reinforcers (see Caggiula et
al., 2009 for review). Nonetheless, to better understand the circumstances in which nicotine
enhanced responding for reinforcing stimuli, Palmatier, O'Brien, and Hall (2012) systematically
altered reinforcer intensity (sucrose concentration), conditioning history, and schedule of
18

reinforcement (effort necessary to obtain sucrose). They hypothesized that the effect of nicotine
was motivational in nature – nicotine increased the motivation to obtain rewards which would be
observed by higher rates of lever responding ("effort"). Thus, the effect of nicotine should be
largest when rats respond for larger rewards (e.g., 0% sucrose vs. 20% sucrose) and easier to
observe under schedules of reinforcement requiring more effort (e.g., progressive ratio (PR)) as
opposed to schedules requiring less effort (e.g., fixed ratio (FR)). In addition to confirmation of
both hypotheses, their findings shed light on the mechanisms by which nicotine might be
‘enhancing reinforcement.’ Nicotine's ability to enhance the effectiveness of reinforcers depends
on the subjects' conditioning history (Palmatier, O’Brien, & Hall, 2012).
When the magnitude of the sucrose reinforcer was manipulated in the same rats (e.g.,
within-subject design), nicotine enhanced responding for all concentrations of sucrose equally –
which suggested one of two possibilities – first, the psychomotor stimulant effects of nicotine
increased nonspecific behavior (Frenk & Dar, 2004). Second, all the reward-predictive stimuli
were congruent in these tests – the same lever predicted all magnitudes of reward delivery. In a
follow-up experiment, researchers used a between-subject manipulation of reward magnitude (0,
5, or 20% sucrose) to ensure conditioning history coincided with one sucrose concentration
(Palmatier et al., 2012). The enhancing effects of nicotine directly correlated with reward
magnitude – nicotine had no effect on responding for rats tested with 0% sucrose, moderately
increased motivation in rats tested with 5% sucrose, and robustly increased motivation in rats
responding for 20% sucrose. This was interpreted as an increase in ‘incentive salience’ of the
reward-predictive cues. When those cues were homogeneous (within-subject manipulation of
sucrose) nicotine enhanced motivation equally across sucrose concentrations. However, when
cues predicted one outcome (a strong reward, a moderate reward, or no reward) the enhancing
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effect of nicotine increased relative as the conditional strength of the predictors increased. Taken
together, the reinforcement enhancing effects of nicotine is dependent upon on reward-predictive
nature of cues (incentives) rather than the strength of the actual outcome (sucrose).
In order to confirm this, a follow-up study (Palmatier et al. 2013) used a Pavlovian
conditioned approach (PCA) paradigm to directly test if nicotine increased the ability of an
incentive to evoke approach behavior. In PCA paradigms brief presentations of a conditioned
stimulus (CS) are immediately followed by the presentation of an appetitive unconditioned
stimulus (US). The CS is usually presented for 8-10 seconds at which time approach to the CS
(sign tracking), or the location where the US will be delivered (goal tracking), can be measured.
Although approaching or manipulating the CS does not result in a contingent delivery of the US,
rats are more likely to approach the cue when pretreated with nicotine (Olausson, Jentsch, &
Taylor, 2003, 2004; Palmatier, Peterson, Wilkinson, & Bevins, 2004; Palmatier et al., 2013;
Raiff & Dallery, 2008). In congruence with previous research, nicotine enhanced sign-tracking
behavior, thus indicating nicotine increased the incentive salience of the reward-predictive CS. In
other words, the stimulus that predicts upcoming reward presentation is more salient to the
animal, and therefore elicits more approach behavior. This enhanced saliency of CSs provides an
explanatory framework for how nicotine functions as a ‘reinforcement enhancer’ even though
perception of the reward (sucrose) is unchanged.
Like nicotine, there is evidence that caffeine enhances motivation for a variety of
reinforcers. Caffeine enhances the motivation for primary reinforcing drugs including cocaine,
amphetamine, alcohol, synthetic cathinones, and nicotine (Cauli, Pinna, Valentini, & Morelli,
2003; Gannon, Galindo, Mesmin, Rice, & Collins, 2017; Green & Schenk, 2002; Kuzmin,
Johansson, Semenova, & Fredholm, 2000; Prieto et al., 2016; Shoaib, Swanner, Yasar, &
20

Goldberg, 1999), intracranial self-stimulation (Lazenka, Moeller, & Negus, 2015), and non-drug
reinforcers (Sheppard et al., 2012). In rats, a bolus dose of 12.5 mg/kg caffeine, a moderate
psychoactive dose, enhances operant responding for two reinforcing stimuli - sucrose (20% w/v)
and a visual stimulus (30s extinguished house light) (Sheppard et al., 2012). Unlike nicotine, the
reinforcement enhancing effect of caffeine declined after repeated daily dosing over fifteen days
and partially returned following four and eight days of abstinence, suggesting that tolerance after
chronic caffeine exposure attenuates drug-induced reinforcement enhancement. Even with the
difference in tolerance between these stimulants, there is strong evidence that caffeine and
nicotine enhance motivation for unconditioned and conditioned reinforcers.
The discovery that caffeine has robust reinforcement enhancing effects may help to
explain the paradox between widespread human caffeine consumption and the sparse evidence
for primary reinforcement in preclinical paradigms. For humans, caffeine is most commonly
consumed in complex oral vehicles (coffee, energy drinks, soft drinks) that are replete with both
unconditioned reinforcers (sugars, sweeteners, and fats) and conditioned reinforcers (coffee,
fruit, and cola flavors). A critical difference between human and pre-clinical caffeine selfadministration may be the co-presentation of non-drug reinforcers in one paradigm (human) and
the lack of non-drug reinforcers in the other (non-human). In preclinical self-administration the
co-presentation of non-drug reinforcers with caffeine has gone untested, but in human studies it
may have potentiated substantial caffeine consumption without much discussion from
researchers. A preclinical model of caffeine self-administration comprised of simultaneous
caffeine and gustatory reinforcer delivery could result in similar results of caffeine intake. This
model could utilize caffeine's ability to alter motivation for incentive stimuli, via enhanced
salience, while using these incentive stimuli to elicit behavior that perpetuates caffeine
21

consumption. If this preclinical model was successful, this would be similar to nicotine selfadministration paradigms. Furthermore, successful results would indicate that these incentive
stimuli, and possibly the cues that temporally predict them, are perpetuating caffeine use via
activation of dopaminergic activity in the reward areas of the brain.
The Mesolimbic Dopamine System, Incentive Salience, and Caffeine
Mesolimbic Dopamine System
The mesolimbic dopamine system is a substrate composed of structures located in the
midbrain, basal forebrain, and cortices of the forebrain (Koob & Volkow, 2010). The Ventral
Tegmental Area (VTA), located in the midbrain, projects dopaminergic signals via the medial
forebrain bundle to the nucleus accumbens (NAc) located in the basal forebrain. The NAc also
receives limbic input from the amygdala, frontal cortex, and hippocampus, thus making it a
highly important and well-studied area for understanding reinforcement and drug addiction
(Koob & Volkow, 2010). Furthermore, mesolimbic dopamine, most notably in the NAc, increase
as a direct result of environmental presentation of rewarding stimuli and the cues that predict
these stimuli (Robinson & Berridge, 1993). For example, regional dopamine activation occurs
more when a reward is expected compared to when a reward is received unexpectedly (Volkow
et al., 2003). In addition, the midbrain dopamine system promotes performance of goal-directed
behavior (Salamone, Correa, Farrar, & Mingote, 2007) as well as activation in general (Le Moal
& Simon, 1991).
While dopamine D1 receptors are found throughout the brain, the majority of dopamine
D2 receptors are found in the striatum (Fredholm, Bättig, Holmén, Nehlig, & Zvartau, 1999).
These dopamine receptors form a heteromer with the receptors for the endogenous ligand
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adenosine (de Lera Ruiz, Lim, & Zheng, 2014). Adenosine mostly plays a regulatory role in the
brain. A byproduct of energy use via ATP, adenosine binds to endogenous receptors which
causes a down regulation in downstream activity (Ferré, 2016). Adenosine A1 and A2A receptors
form heteromers with dopamine D1 and D2 receptors, respectively, and share an antagonistic
relationship. In other words, activation of adenosine receptors results in reduced activation of the
corresponding dopamine receptor (Ferré, 2016). On the other hand, caffeine indirectly increases
dopaminergic activity via antagonism of adenosine A1 and A2A receptors (Ferré, 2016). If
caffeine antagonizes adenosine, then there should be an observable increase in dopaminergic
activity in areas receiving dopaminergic input such as the NAc. To the contrary, there are mixed
findings on the dopamine-enhancing effect of caffeine within the ventral striatum. An acute
bolus dose of caffeine (30 mg/kg) weakly enhances dopaminergic activity in the NAc shell
(Quarta, Borycz, et al., 2004; Solinas et al., 2002). Conversely, other studies have found no
observable increases in NAc shell dopamine efflux with similar injection procedures (Acquas,
Tanda, & Di Chiara, 2002; De Luca, Bassareo, Bauer, & Di Chiara, 2007). No changes in
accumbal dopamine efflux after researcher-administered caffeine may explain why contingent
caffeine presentations are unable to sustain reliable, robust self-administration in preclinical
models (Acquas et al., 2002; De Luca et al., 2007). However, caffeine dose-dependently
reinstates extinguished cocaine seeking and can be attenuated through non-selective D1/D2
antagonists, therefore suggesting caffeine is increasing NAc dopamine efflux (Green & Schenk,
2002). In other words, when paired with a primary reinforcer, caffeine promotes dopamine
release in the NAc. Extracellular dopamine in the NAc is directly related to incentive salience
and is hypothesized to play a causal role in substance dependence (De Mei, Ramos, Iitaka, &
Borrelli, 2009; Robinson & Berridge, 1993). Accordingly, caffeine may promote goal-directed
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behavior towards primary reinforcers and the cues that predict them by enhancing the dopamine
response elicited by these stimuli.
Caffeine and Goal-Directed Behavior
Caffeine, like nicotine, has multiple effects on goal-oriented behavior: enhancing operant
responding for primary reinforcers (as previously discussed), changing novel stimuli to
conditioned reinforcers via pairing with the drug (Yeomans, Durlach, & Tinley, 2005; Yeomans,
Mobini, & Chambers, 2007), and possibly as a primary reinforcer itself as suggested in some
research with human volunteers (Evans et al., 1994; Griffiths & Chausmer, 2000; Schuh &
Griffiths, 1997). In addition to the drug’s ability to enhance responding for reinforcers, caffeine
alters sensitivity to other illicit drugs as seen by the enhancement of psychomotor effects of
stimulants such as amphetamine, cocaine, nicotine, as well as promoting the reinstatement of
cocaine-seeking after extinction (Green & Schenk, 2002; Horger, Wellman, Morien, Davies, &
Schenk, 1991; Magill et al., 2003; Palmatier & Bevins, 2001; Spealman, Barrett-Larimore,
Rowlett, Platt, & Khroyan, 1999; Worley, Valadez, & Schenk, 1994). Caffeine enhances
motivation for other incentive stimuli in a way that could perpetuate drug use or elicit caffeine
consumption congruent to reported public use.
Other than illicit drugs, incentive stimuli (primary and conditioned reinforcers) acquire
the ability to control behavior, specifically goal-directed behavior, through multiple pairings with
caffeine. This produces a conditioned motivation state that perpetuates caffeine consumption
(Fedorchak, Mesita, Plater, & Brougham, 2002; Myers & Izbicki, 2006; Yeomans, Javaherian,
Tovey, & Stafford, 2005). For example, researchers performed a study looking at the difference
in attentional bias to caffeine-related words between high, moderate, and low caffeine
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consumers. Following overnight abstinence, volunteers participated in a modified dot-probe task
with a mix of words associated with caffeine and neutral control words. Only high caffeine users
showed an attentional-bias to caffeine-related words which correlated with self-reported typical
caffeine consumption and caffeine craving (Yeomans, Javaherian, et al., 2005).
Novel Flavors
In addition to enhancing preference for drug-associated environments and words, caffeine
enhances preference for novel olfactogustatory stimuli. Flavors previously paired with caffeine
are later preferred in a choice task over unpaired flavors (Fedorchak et al., 2002; Kendler, Myers,
& Gardner 2006; Yeomans, et al., 2005; Yeomans, Spetch, & Rogers 1998). Specifically,
caffeine associated flavors are preferred, perceived as more palatable, and chosen more often
than non-associated flavors (Fedorchak et al., 2002; Yeomans, Durlach, et al., 2005; Yeomans et
al., 1998). Caffeine, like nicotine, is altering the preference, and motivation for both novel and
rewarding stimuli. Although nicotine and caffeine target different receptors in the brain, both
psychostimulants affect reward learning and goal-directed behavior in a similar fashion.
Although researchers have established that caffeine enhances the reinforcing effects of
drug (Horger et al., 1991) and non-drug reinforcers (Schenk, Worley, McNamara, & Valadez,
1996; Sheppard et al., 2012), it is unclear if caffeine is enhancing the motivational properties of
rewards or their associated cues in these paradigms. If caffeine is priming the incentive system,
and therefore increasing the effect of incentive stimuli to promote NAc dopamine release, then
caffeine should enhance sign-tracking in a PCA paradigm. To test this hypothesis, we examined
the effects caffeine on sign- and goal-tracking behavior. Furthermore, we hypothesized that the
enhancement of incentive salience by caffeine will be associated with increased extracellular
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dopamine in the NAc. In order to observe co-occurring dopamine efflux, rats will be
instrumented with microdialysis probes in the NAc shell to measure extracellular dopamine
following the acquisition phase of conditioning.
Research Questions Addressed in this Dissertation
1. Is consistent caffeine self-administration possible?
Caffeine enhances motivation for a diverse range of primary reinforcing stimuli including
gustatory stimuli, visual stimuli, and drugs of abuse (O’Neill et al., 2016; Prieto et al., 2016;
Sheppard et al., 2012; Sweeney, Levack, Watters, Xu, & Yang, 2016). If caffeine is delivered
contingently with a primary reinforcer, as is common in human caffeine consumption, animals
may achieve a psychoactive dose of the drug which may promote self-administration. We will
test the hypothesis that consistent caffeine self-administration is possible when delivered
contingently with a primary reinforcer, saccharin, and will result in higher levels of responding
and reinforcers earned compared to saccharin alone or caffeine alone reinforcers. In addition, we
hypothesize that consistent caffeine self-administration will generalize to different routes of drug
administration.
2. Does caffeine administration increase approach to incentives (i.e., 'sign-tracking')?
Although caffeine functions as a reinforcer, no previous study has established whether
caffeine's reinforcement enhancing effects are due to the drug's ability to enhance the salience of
incentive stimuli or inflate the rewarding or pleasurable properties of a reward. We will test the
hypothesis that caffeine increases the salience of an incentive stimulus by recording sign- and
goal-tracking behavior in a PCA paradigm.
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3. Are the putative incentive-promoting effects of caffeine associated with increased NAc
dopamine release?
All drugs of abuse alter the incentive systems of the brain via facilitation of mesolimbic
dopamine signaling (Robinson & Berridge, 1993). Caffeine enhances motivation to obtain
primary reinforcers which may promote caffeine self-administration when the drug and another
primary reinforcer are presented together (Sheppard et al., 2012). One hypothesis for the effect
of caffeine on goal-directed behavior is that caffeine primes the mesolimbic dopamine system
and enhances the response to another reward. However, this hypothesis has not been tested.
Previous research has shown only weak or no increases in NAc shell dopamine efflux after an
acute caffeine dose (Acquas et al., 2002; De Luca et al., 2007; Quarta, Ferré, et al., 2004; Solinas
et al., 2002). We will test the hypothesis that a moderate dose of caffeine will elicit an elevation
in NAc dopamine efflux when exposed to an incentive stimulus that has previously predicted
sucrose presentation.
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CHAPTER 2
METHODS
Subjects
Male Sprague-Dawley rats (Charles River) weighing approximately 350g upon arrival
were used in this study. Subjects were individually housed in a temperature and humidity
controlled environment with a reverse 12:12 h dark:light cycle. All behavioral testing was
conducted during the dark part of the light cycle. Subjects were maintained on a restricted diet of
approximately 17g of rat chow (LabDiet, St.Louis, MO) throughout the experiment to ensure
motivation for an aqueous sucrose or saccharin solution. Access to diet was provided
immediately following behavioral testing and tap water was provided ad libitum in the home
cage throughout the experiments. Methods were approved by the Institutional Animal Care and
Use Committees at East Tennessee State University (Animal Welfare Assurance #: A3203-01).
Apparatus
Conditioning Chambers
Experimental sessions were conducted in ten Med-Associates (Georgia, VT) operant
chambers (ENV-008CT) measuring 30.5 × 25.4 × 30.5 (w×d×h) individually housed in a
ventilated, sound and light attenuated enclosure. Chambers were equipped with two retractable
levers (ENV-112CM) and stimulus lights located 15 cm above the grid flooring on the same
instrument panel where a liquid dipper receptacle was located. Levers were located on either side
of the receptacle, approximately 2 cm in from the outside of the instrument panel. A liquid
dipper with a 0.1 ml cup attached to a motorized arm delivered a sucrose or saccharin solution
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into the receptacle which served as the reinforcer or US in these experiments. For experiment 3
extension of one lever and simultaneous illumination of the right stimulus light for 30s served as
the conditioned stimulus stimuli. A Med Associates contact lickometer controller (ENV-250)
was attached to the back of the left lever in order to record lever contacts when extended into the
operant chamber. An infrared emitter detector unit recorded entries into the receptacle
throughout the session. Two houselights were located on both instrument panels approximately
28.5 cm above the floor and 12.2 cm from the outer walls of the operant chamber. Each operant
conditioning chamber was also equipped with a drug delivery system with a syringe pump (MedAssociates, model PHM100 – 10 rpm) that was used to deliver intravenous drug during
Experiment 1. A computer using MED-PC V software programming controlled the operant
chambers and recorded all data.
Microdialysis Collection Assembly
Dopamine dialysate was collected by connecting the microdialysis probe directly to a
microdialysis collection assembly. The assembly was constructed with two pieces of tubing. One
side connected to a swivel that perfused aCSF towards the probe in the rat’s brain. This side was
constructed 29 cm of PE20 tubing. The other side collected aCSF coming from the microdialysis
probe and was constructed of 29 cm of PE10 tubing with a ball 3 cm from the end. The plastic
ball secured an amber vial and cap to the line and the amber vial was exchanged every 20
minutes.
High Performance Liquid Chromatography (HPLC)
Dopamine dialysate was analyzed through electrochemical detection via graphite
electrode using a EiCOM HTEC-510 HPLC machine (San Diego, CA). Dialysate samples were
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analyzed manually by placing 5-20 µl of sample into a 50 µl loop. Alternatively, 20 µl dialysate
samples could be run using a EiCOM AS-700 autosampler (San Diego, CA). A computer using
Envision software programming controlled EiCOM equipment and quantified dialysate sample
using an area-under-curve analysis.
Drugs and Solutions
Oral Solutions
Saccharin (Sigma-Aldrich, St. Louis, MO) was dissolved in tap water (0.2%, w/v).
Caffeine anhydrous (Sigma-Aldrich, St. Louis, MO) (0, 2.5, 3.5, 5.0, and 7.0 mg/ml) was
dissolved in tap water with saccharin (0.2%, w/v), decaffeinated instant coffee (0.5% w/v), or
both saccharin (0.2%, w/v) and decaffeinated instant coffee (0.5%, w/v). Sucrose (20% w/v) was
comprised of table sugar diluted in tap water. All oral solutions were delivered in 0.1 ml dipper
cups.
Intravenous Solutions
Caffeine anhydrous (Sigma-Aldrich, St. Louis, MO) was dissolved in 0.9% sterile saline
and infused at a volume of 0.2 ml/kg/infusion intravenously. Sterile saline solution (0.9%
Sodium Chloride) was prepared using sterile water and sodium chloride (Acros Organics, New
Jersey) and delivered via Intra peritoneal (IP) injection at a volume of 0.2 ml/kg. Caffeine
anhydrous (Sigma Aldrich, St. Louis, MO) was diluted in a sterile saline solution at 5 mg/ml and
delivered via IP injection at .2 ml/kg to achieve a dose of 10 mg/kg.

30

Microdialysis Solutions
Artificial cerebrospinal fluid. Artificial cerebrospinal fluid (aCSF) microdialysis
perfusion medium was composed of 145.0 NaCl, 2.7 KCl, 1.0 MgCl2, 2.5 CaCl2, and 2.0
Na2HPO4. aCSF was filtered through a sterile filter (pore size, 0.2 µM), and prepared the day of
microdialysis sessions. When necessary, the pH was adjusted to 7.4 with 0.1 N acetic acid. aCSF
was perfused through 2 mm loop-style probes (described below) at a rate of 1.1 µl/min. Dialysate
samples were preserved using 5 µl of DA preservative in each sample collection tube.
Dopamine mobile phase. Dopamine mobile phase used for dopamine dialysate analysis
via HPLC was composed of 1400 ml HPLC H20, 328 µl acetic acid, 10.36 g ammonia acetate,
600 ml methanol, 14.2 g sodium sulfate, and 2 ml of 50 mg/ml EDTA. Mobile phase volume was
adjusted to 2000 ml using submicron filtered HPLC H20 (Fischer Chemical, St.Louis, MO).
Dopamine preservative. Dopamine preservative was used for dialysate sample
collection and HPLC analysis. Dopamine preservative consisted of 0.1 mol phosphate buffer
with 0.1 mmol EDTA. Preservative was filtered through a sterile filter (pore size, 0.2 µM) before
use.
Dopamine standard. Dopamine standard was used for HPLC calibration and dopamine
detection. Standard was composed of dopamine hydrochloride (Alfa Aeser, Ward Hill, MA) and
diluted to a concentration of 5 nM using dopamine preservative.
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Procedures
Experiment 1 and 2
Training. Rats from Experiments 1 and 2 were trained to lever press to gain access to a
saccharin solution. Initially, the left lever was inserted into the operant chamber for 15 s and
immediately followed by activation of the liquid dipper (lowered into saccharin solution for 0.5
s) to gain access to 0.1 ml of saccharin solution. Any responses recorded during the lever
presentation resulted in retraction of the lever and 2 activations of the liquid dipper, separated by
5 s. Successful shaping was operationally defined as earning 60 reinforcers within a 1-h session.
Surgery. Rats were anesthetized with isoflourane and implanted with an indwelling
jugular vein catheter. Jugular vein catheters were constructed using a blunt needle (22 G x 11/2”, EXEL Int., California) bent at a 90° angle approximately 2 mm below the hub. A nylon
washer (.09x.25x.062) (Fastenal, Minnesota) was placed at the base of the needle followed by a
round patch of polyester fabric (37.5 mm diameter) and another washer. Silastic® tubing (Dow
Corning, Michigan) (0.51 ID x 0.94 mm OD) approximately 175 mm in length was attached to
the needle up to the bend. The needle, washer, patch, and tubing was secured into place using
medical device epoxy adhesive (LOCTITE EA M-21 HP, Henkel, North Carolina). A silicone
ball (3 mm diameter) was attached 40 mm from the end of the tubing using 100% RTV silicone
(DAP, Maryland). Subcutaneous ketoprofen injections (3 mg/kg) were used to alleviate pain for
three days after surgery. Catheters were flushed daily with sterile heparinized saline (30 IU) and
Timentin (40 mg/kg, bioWorld, Dublin, OH). Operant testing began 7-10 days after surgery to
allow full recovery from the surgical procedure.
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Intravenous caffeine self-administration. Following the training procedure, rats (n=60)
were habituated to lever press for access to saccharin under a progressive ratio (PR)
reinforcement schedule during a 60 min session for four sessions. The PR was exponential,
adapted from Richardson and Roberts (1996), and used previously to investigate the
reinforcement enhancing effects of nicotine (Palmatier et al., 2007) and caffeine (Sheppard et al.,
2012). Rats in the 1.0 mg/kg C+S group did not receive any habituation sessions. This did not
seem to lower acquisition rates or motivation for the assigned reinforcer. Following habituation,
rats were randomly assigned to one of three groups: saccharin only (S, n=10), caffeine only (C,
n=23) or saccharin and caffeine (C+S, n=27). For rats in the S group meeting the schedule of
reinforcement on the active lever resulted in presentations of 0.2% saccharin. Rats in the C group
were randomly assigned to one of 4 unit doses (mg/kg/infusion) of caffeine, 0.125 (n=6), 0.5
(n=6), 1 (n=5), or 4 mg/kg (n=6) and these infusions replaced saccharin presentations for
meeting the schedule of reinforcement on the active lever. For rats in the C+S group both 0.2%
saccharin and IV caffeine infusions 0.125 (n=7), 0.5 (n=9), 1.0 (n=5), or 4.0 mg/kg (n=6) were
presented for meeting the schedule of reinforcement on the active lever. Caffeine dose was a
between subjects factor; each rat received only one unit dose throughout the study. Rats were
adapted for self-administration of saccharin and/or IV caffeine via lever pressing under a PR
reinforcement schedule. Before the start of the session rats receiving intravenous caffeine had a
leash attached to their catheter port located between their shoulders for caffeine administration.
The leash was counterbalanced to minimize constriction of movement from the weight of the
leash. At the start of each session both the active (left lever) and inactive (right lever) were
inserted into the operant conditioning chamber; the inactive lever had never been presented
before testing began. A 30 second time-out period occurred in which the house light was
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extinguished; lever presses were recorded but were not counted toward the schedule of
reinforcement. All sessions ended after 60 min, with breaking points operationally defined as 5,
10, or 20 min periods without earning a reinforcer during the session. Sessions were conducted
48 hr apart to avoid tolerance to caffeine. After five days of testing catheter patency was
confirmed with propofol (0.2-0.3 ml infusion); only data from rats displaying immediate loss of
muscle tone, heart rate, and righting reflex were included in the analyses.
Oral caffeine self-administration. The purpose of this experiment was to determine
whether caffeine would be self-administered orally in a vehicle that included a reinforcing
gustatory stimulus (0.2% saccharin). All rats were habituated to a saccharin solution for three
days under a PR schedule and one day of an FR1 schedule of reinforcement. Following
habituation, rats were assigned to their reinforcer condition and responded under a PR schedule
with a 30 minute breakpoint (30 minutes passing without earning a reinforcer). Session length
varied between individual rats since sessions did not end until rats reached the 30 minute
breakpoint. Forty rats were assigned to one of three vehicles (Water (W), Saccharin (S), or
Decaffeinated coffee +Saccharin (DS)) with caffeine (henceforth indicated by a + symbol) or
without caffeine (henceforth indicated by a – symbol) for completing the schedule of
reinforcement on the active lever. Twenty rats received caffeine in a liquid vehicle that either
contained saccharin (S+, n=7, DS+, n=7) or just water (W+, n=6). The remaining rats received
water (W-, n=6) or saccharin alone (S-, n=7, DS-, n=7) for meeting the contingency. Rats in the
caffeine (+) groups were first exposed to a liquid reinforcer with 2.5 mg/ml caffeine
concentration. Sessions continued with this concentration until responding stabilized – an
informal assessment of group-wise responding was used to determine stability (no linear trend
across the last 3 days of testing). Caffeine concentration was increased after group stability in the
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following order: 2.5, 3.5, 5, and 7 mg/ml. Rats in the caffeine group responded for 2.5 mg/ml for
six days, 3.5 mg/ml for three days, 5.0 mg/ml for five days, and 7.0 mg/ml for four days. Unlike
Experiment 1, each concentration of caffeine was experienced by all caffeine (+) groups.
Experiment 3
Group assignment. Rats (n=60) were randomly assigned to one of three drug conditions:
10 mg/kg caffeine (10 mg/kg, n=16), 25 mg/kg caffeine (25 mg/kg, n=20) or saline (0 mg/kg,
n=24). Assigned drug injections were delivered via intraperitoneal injection (IP) fifteen minutes
prior to the start of each conditioning session. All sessions occurred on alternate days to avoid
the development of caffeine tolerance. Following conditioning, rats were randomly assigned to
one of two microdialysis testing groups (CS or No-CS; see Conditioning).
Conditioning. Following pretreatment, rats were placed in operant chambers for one
hour conditioning sessions. During conditioning sessions rats were exposed to 15 pairings
between the CS and US. Since the ‘goal’ location (receptacle where US was delivered) was
continuously available, approach was recorded during Pre-CS intervals (the 15s preceding each
CS presentation). During the CS intervals the left lever was extended into the chamber and the
stimulus light above the lever was illuminated for 15 seconds. US intervals began once the
dipper was cycled to deliver a 0.1 ml dipper presentation of sucrose solution (US) that was
available until the next US delivery. Conditioning trials did not occur in the first or last eight
minutes of the session and were separated by inter-trial intervals that averaged 120 s (90-150 s).
Lever contacts, presses, and dipper receptacle entries were recorded throughout the session.
Lever contacts and presses during CS intervals are considered measures of 'sign-tracking.' Dipper
receptacle entries during the CS intervals are measures of 'goal-tracking.' There were 8 total

35

conditioning sessions – the first five lasted approximately 1 h. Ten rats received an 8th
conditioning session because of experimenter error (4 rats in the 10 group and 6 rats in the 0
group); during the 6th testing session the dipper receptacles were left in a locked position and CS
presentations were not followed by US presentations.
Sessions 6 and 7 served as microdialysis habituation; rats were placed in operant
chambers for 2 h prior to the start of the conditioning session and left in the apparatus for 1 h
after the session was completed to simulate the microdialysis sample collection. The door to the
sound-attenuating chambers was left open to mimic conditions during sample collection.
Microdialysis samples were collected on the 8th test day and tests were conducted in ‘extinction’,
meaning that the US was never presented. Rats in the CS groups were exposed to CS
presentations during the microdialysis session. Rats in the No-CS group did not experience any
CS presentations during microdialysis to investigate the effects of caffeine alone on extracellular
DA. Sample collection lasted 4 h, with a washout (60 min), baseline (60 min), testing session (60
min) and post-test samples (60 min).
Cannula and probe implantation. Following the 7th conditioning session all animals
underwent stereotaxic surgery to implant a cannula for microdialysis. Rats were anesthetized
using 2% isoflurane, placed in a stereotaxic instrument in which ear and incisor bars were
adjusted to ensure a flat skull position (level lambda and bregma height), and implanted
ipsilaterally with one 18 gauge cannula (Plastics One Inc., Roanoke, VA) approximately 1 mm
above the targeted brain region. The targeted region was the shell of the Nucleus Accumbens
using the following stereotaxic parameters: + 1.7 mm Anterior from bregma, +2.3 Lateral to
midline, and -5.4 Ventral from the dura mater at a 10° angle. Dummy stylets were placed into the
cannula following surgery and remained until the microdialysis collection session. Rats rested
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for a minimum of 5 days in their home cage for recovery prior to dialysate collection. On the
final day of recovery, a loop style microdialysis probe was inserted into the shell of the nucleus
accumbens following the 7th habituation session.
Microdialysis. Approximately 16 hours after microdialysis probe implantation, rats were
placed into operant boxes after connecting probes to a collection assembly using 23 G 1 ¼
needles (Becton Dickinson, Franklin Lanes, NJ). The collection assembly was connected to a
swivel (type) located on a Gimbal ring attached to a drug delivery arm (Med Associates, PHM110-SAI). The swivel was connected to a Harvard pump using P20 tubing (Braintree Scientific,
Braintree, MA). Microdialysis aCSF was perfused at a flow rate of 5µl/min until aCSF was
continuously flowing through the probe. Once confirmed for all rats, flow rate was changed to
1.1 µl/min for the remainder of the session. Following a one hour washout period, four 20-min
baseline samples were taken. Rats were given an IP injection of their assigned drug at the start of
the fourth sample collection. After baseline, rats in the CS group were exposed to 15 CS
presentations over a one hour period. Rats in the No-CS group received no CS presentations
during this hour. Following CS/No-CS presentations, three 20-min post dialysate samples were
collected. All dialysate samples were collected in a labeled microfuge vial containing 5 µl of
dopamine preservative, then immediately frozen using dry ice and stored at -80° C.
Histology. Immediately following microdialysis testing, rats were euthanized with an
overdose of CO2 inhalation. Bromophenol blue (1%; 0.5µl) was perfused into the shell of the
nucleus accumbens via dialysis probe. Brains were then extracted, frozen on dry ice, and stored
at -80° C. Brains were later sectioned (40 µm) using a cryostat microtome. Brain sections
containing bromophenol blue stain were placed on glass slides. Sections were examined to verify
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probe placement using the rat brain atlas of Paxinos and Watson (2005). Animals with a probe
location outside the NAc shell were excluded.
Dialysate analysis. All samples were analyzed using high-pressure chromatography
(HPLC) with electrochemical detection using instruments described above. Samples were
removed from the -80 freezer and 25 µl of each sample was pipetted into a 96 well sample plate.
Plates were placed into an autosampler where each well was sampled individually. Samples
containing less than 25 µl were filled with dopamine preservative to reach an overall volume of
25 µl. Sample amount was noted and dopamine sample was corrected after analysis. Dopamine
concentration was determined using the area-under-curve analysis for each histogram. Samples
were analyzed over a 14 min time span to allow analysis of entire sample without contaminating
analysis of upcoming sample.
Data Analyses
Caffeine Self-Administration
In Experiment 1, data were analyzed with a mixed-factors ANOVA on active lever
presses, inactive lever presses, and reinforcers earned, including Group (C+S vs. S vs. C) and
Session (1-5, repeated) as the independent factors. This was done to ensure reliable caffeine selfadministration over multiple days. For Experiment 2, the concentration of caffeine was the
critical manipulation so the mixed factors ANOVA on lever presses and reinforcers earned
including Group (DS+, DS-, S+, S-, W+, W-) and Dose (2.5-7 mg/ml, repeated) as the
independent factors. Lever presses and reinforcers earned at the 20 min break point were
analyzed due to the increase in inactive lever presses in caffeine groups during the final half hour
of each session. Final two day averages of lever presses and reinforcers were used in the analysis
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to compare caffeine concentrations. These two day averages provided stable rates of selfadministration that were representative of each group at each caffeine concentration. For
Experiments 1 and 2, second-order contrasts were used to compare groups on individual sessions
(Experiment 1) and individual doses (Experiment 2). Break points (Experiments 1 and 2) were
not included in the analysis because the PR schedule increased at an exponential rate (0.12),
therefore violating the assumption of linearity and thus increasing the susceptibility of a Type II
error.
Pavlovian Conditioned Approach
PCAI. The extent to which a rat emitted more sign- or goal-tracking behaviors during
sessions was quantified using a compound index. The index incorporated three measurements of
Pavlovian conditioned approach which occurred during the 15s CS interval: Probability
difference score, Response bias score, and a Latency difference score. The Probability difference
score [P(sign) - P(goal)] is the difference in probability of entry into the dipper well (P (goal))
subtracted from the probability of a lever contact or press (P(sign)). Probability of sign- and
goal-tracking for each CS trial is scored as a 1 or 0 dependent upon whether a rat entered a
receptacle or contacted the lever (1=yes, 0=no). For example, if a rat contacted the lever during
all 15 CS presentations, the P(sign) would be scored as a 15. The response bias score reflects the
difference between lever contacts and receptacle entries during each CS period [(total lever
presses - total receptacle entries)/(total lever presses + total receptacle entries)]. The Latency
difference score [(lever contact latency - receptacle entry latency)/15] is the difference in latency
to contact the lever and latency to enter the dipper well. Together, these measurements were
formulated to form the Pavlovian Conditioned Approach Index (PCAI) [(Probability difference
score + Response bias score + Latency difference score)/3]. Scores range from -1.0 to +1.0
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indicating a strong bias to the dipper receptacle entry (-1.0) or a strong bias to contact the lever
(+1.0).
Acquisition. Separate 2-way (dose x session) Mixed Factors ANOVAs were conducted
for the acquisition portion of the experiment on PCAI, Probability difference score, P(sign),
P(goal), Response bias score, lever contacts, dipper receptacle entries, Latency difference score,
lever contact latency, and receptacle entry latency with Dose (0, 10, 25 mg/kg) and Session (1-7)
as independent factors. Session was treated as a within-subject variable during acquisition.
Caffeine dose was treated as a between-subjects variable since individual rats only received
repeated administration of the same dose throughout the experiment. Significant main effects on
dose were probed using Dunnett's test with the 0 mg/kg group serving as the reference group for
comparison with the 10 mg/kg and 25 mg/kg groups. Significant interactions were followed up
with simple effects analyses and t-tests where appropriate.
Goal-Tracking. For conditioning and microdialysis sessions head entries into the dipper
receptacle were recorded in 15 s bins during the Pre-CS and CS intervals. Pre-CS intervals were
used to measure baseline head-entry behavior in the dipper well. Head-entries during CS
presentations were measured in order to determine the elevation score (Palmatier et al., 2004).
Elevation scores were calculated by subtracting head-entries during the Pre-CS bins from headentries during the CS bins. Elevation scores from each bin were averaged for each session and
used as the primary dependent variable for goal tracking behavior. Scores above a theoretical
mean of zero indicate that a rat spent more time entering the dipper well during CS presentation.
In addition, latency to enter the dipper receptacle during CS trial was recorded and reported as an
average at the end of each session. Dipper receptacle entries and receptacle latency were used to
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determine receptacle entry score, receptacle latency score, and P(goal). These components are
needed to determine PCAI and indicate goal-tracking behaviors.
Sign-Tracking. For conditioning and the microdialysis session lever contacts and presses
were recorded in 15 s bins during each CS interval and reported as the cumulative total at the end
of each session. Latency to contact the lever during each CS trial was recorded and reported as
an average at the end of each session. Lever contacts, presses, and latency to lever contact were
used to determine lever contact, contact latency score, and P(sign). These components are needed
to determine PCAI and indicate sign-tracking behaviors.
Microdialysis
Dopamine. Dopamine efflux was normalized by averaging the first three baseline
microdialysis samples collected after the initial 1 h washout period. Remaining samples were
calculated as a percentage of baseline value. Only samples representative of dopamine efflux
during CS exposure and afterwards were analyzed for group comparisons. Samples 6-8
represented dopamine efflux during CS exposure (Test Interval) and samples 9-11 represented
dopamine efflux after CS exposure (Post Test Interval). Percent change from baseline dopamine
samples collected during Test and Post Test intervals were transformed for Area Under the
Curve (AUC) analysis. Group AUC averages during the Test Interval and Post Test Interval were
used to analyze the main effects of Dose and Interval. Separate analyses were conducted for
groups exposed to the CS and groups not exposed to the CS. Final statistical analyses include
only rats with confirmed accumbal shell probe placement. Changes in dopamine using AUC
calculated data was analyzed by separate 2 x 3 (Interval x Dose) ANOVA for groups exposed to
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the CS and not exposed to the CS. Pairwise comparisons using Bonferroni’s adjustment was used
to examine interactions between caffeine dose and intervals.
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CHAPTER 3
RESULTS
Caffeine Self-Administration
Experiment 1
Acquisition. Caffeine dose-dependently promoted self-administration when contingently
paired with a saccharin reinforcer (C+S) relative to control groups that received caffeine (C)
infusions or saccharin alone (S). This conclusion was supported by omnibus 2 x 4 x 5 (Group x
Dose x Session) ANOVA on the reinforcers earned dependent measure. There was a significant
main effect of Group, F(1,43)=67.712, p<.001, as well as significant Session x Group,
F(3.943,169.551)=2.344, p<.001, Dose x Group, F(3,43)=3.831, p=.016, and Session x Dose x
Group, F(11.829,169.551)=2.62, p=.003, interactions. Pairwise comparisons revealed C+S
groups earned more reinforcers than C groups at the .125 mg/kg/infusion dose on sessions 1-5
(p’s<.05, Fig. 1A), 0.5 mg/kg/infusion dose on sessions 2-5 (p’s<.05, Fig.1B), 1.0
mg/kg/infusion on sessions 2-5 (p’s<.05, Fig.1C), and 4.0 mg/kg/infusion dose on session 2
(p<.05, Fig. 1D). An omnibus 2 x 4 x 5 (Group x Dose x Session) ANOVA on active lever
responses revealed a significant Session x Group interaction, F(2.207, 94.891)=5.711, p=.003.
Posthoc pairwise comparisons with Bonferroni adjustment revealed C+S groups had more active
lever responses than C groups at the .125 (Sessions 1-4, Fig. 1E), 0.5 (Sessions 2-5, Fig.1F), and
1.0 doses (Sessions 2-5, Fig. 1G). A 2 x 4 x 5 (Group x Dose x Session) ANOVA was conducted
on inactive lever presses and revealed no main effects or interactions. Taken together, these
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Figure 1: Low-to-moderate doses of caffeine enhance acquisition of self-administration when
paired with dipper presentations of liquid saccharin. Figures A-D represent reinforcers earned for
each group on each day of caffeine self-administration. Figures E-H represent active and inactive
lever presses for each group on each day of caffeine self-administration. Asterisks (*) represent
C+S being significantly higher than C groups as determined through pairwise comparisons using
a Bonferroni adjustment (p’s<.05).
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analyses reveal that caffeine, when paired with saccharin, can promote consistent selfadministration at moderate to high doses. Furthermore, group differences were not caused by a
nonspecific psychomotor stimulant effect of caffeine as seen by the lack of significant
differences of inactive lever presses between groups.
Dose response curve. To further assess the ability of caffeine to promote selfadministration when contingently paired with a saccharin reinforcer, C+S groups were compared
to S groups during the final two days of acquisition at each dose. Only the final two days were
main effect of Dose, F(4,70)=9.395, p<.001, on reinforcers earned (Fig.2A). Pairwise
comparisons with Bonferroni adjustment found that the C+S groups receiving 0.5 and 1.0
mg/kg/infusion earned more reinforcers than S groups, p's≤.002. Additionally, the C+S group
receiving 0.5 mg/ml earned more reinforcers than the C+S group receiving 4.0 mg/kg/infusion,
p=.003 (Fig. 2A). Furthermore, a One-Way ANOVA revealed a significant main effect of Dose,
F(4,70)=8.968, p<.001, on active lever presses (Fig. 2B). Pairwise comparisons with Bonferroni
adjustment revealed that the C+S group receiving 0.5 mg/kg/infusion responded significantly
more than the S group, the C+S group receiving.125 mg/kg/infusions, and 4.0 mg/kg/infusions,
p's≤.015 (Fig. 2B). Caffeine's ability to promote self-administration, when contingently paired
with saccharin, at moderate doses was not caused by a nonspecific psychomotor stimulant effect
of caffeine as seen by a non-significant effect of Dose on inactive lever presses (p>.05, Fig. 2B).
The C group was not included in this analysis because there was no control group receiving 0
mg/kg caffeine infusions alone.
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Figure 2: Intravenous delivery of caffeine dose-dependently increases self-administration when
paired with dipper presentations of liquid saccharin. Figure A illustrates the final two day
average reinforcers earned across doses of caffeine. One-Way Between Groups ANOVA
revealed a significant main effect of Dose, p<.001, on reinforcers earned. Figure B illustrates
final two day averages of active and inactive lever presses across doses of caffeine. One-Way
Between Groups ANOVA revealed a significant main effect of Dose, p<.001, on active lever
presses. Asterisks (*) represent C+S being significantly higher than the S group as determined
through pairwise comparisons using a Bonferroni adjustment (p’s<.05).
Experiment 2
Acquisition. Oral administration of caffeine paired with saccharin increased motivation
under the PR schedule of reinforcement. During acquisition, a vehicle containing saccharin and
2.5 mg/ml of caffeine significantly increased motivation compared to groups receiving caffeine
alone. This was confirmed by a 3 x 6 (Vehicle x Session) ANOVA that revealed significant main
effect of Vehicle, F(2,17)=5.766, p=.012, and approaching significance for Session,
F(2.708,40.035)=2.605, p=.069, on reinforcers earned. Planned pairwise comparisons revealed
rats working for vehicles containing saccharin and caffeine earned significantly more reinforcers
than rats receiving vehicles containing caffeine alone, p's≤.019 (Fig. 3A). As expected, there was
also a significant main effect of Vehicle, F(2,17)=4.748, p=.023, and approaching significance
for Session, F(2.657,45.164)=2.596, p=.071, on active lever presses (Fig. 3B). Notably, there
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was no main effects of Vehicle or Session on inactive lever presses, p’s>.05 (Fig. 3B). Vehiclealone groups (S-, DS-, W-) were not statistically different across acquisition. This was confirmed
using separate 3 x 6 (Vehicle x Session) ANOVA on reinforcers earned, active, and inactive
lever presses. There were no significant main effect of Vehicle, Session or interaction across
acquisition, p’s>.05 (Fig. 3A, 3B).

Figure 3: Caffeine delivered in a vehicle containing saccharin increases self-administration
across sessions. Figure A illustrates average reinforcers earned throughout each session of
acquisition. A concentration of 2.5 mg/ml caffeine was used for acquisition for groups receiving
caffeine. Sacc session represents data from baseline procedures in which rats responded for a
saccharin solution only. Figure B illustrates average lever presses throughout each session of
acquisition. Separate Repeated Measures Mixed ANOVAs revealed significant main effects of
Drug and Vehicle on all dependent measures, p’s<.05. Second-order contrasts revealed that DS+
and S+ groups responded more on the active and inactive lever and earned more reinforcers than
the S- group.
Concentration response curve. Caffeine increased responding for the saccharincontaining vehicles across much of concentrations tested. This conclusion was supported by a 3
x 4 (Vehicle x Concentration) ANOVA which revealed a significant main effect of Vehicle,
F(2,37)=26.263, p=.001, on reinforcers earned. The Vehicle x Concentration interaction did not
reach statistical significance, p=.063 (Fig.4A). As expected, an identical pattern was observed for
active lever responses (Fig. 4B). Planned pairwise comparisons using Bonferroni correction
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revealed that caffeine, when paired with a vehicle containing saccharin, increased the number of
reinforcers earned at every concentration (p's≤.008) except 7 mg/ml (p's=.102), when compared
to water. Planned pairwise comparisons revealed similar effects on active lever presses, p's≤.005
(Fig. 4B). Lastly, a 3 x 4 (Vehicle x Concentration) ANOVA revealed a significant main effect
of Vehicle, F(2,37)=6.017, p=.005, on inactive lever presses. Planned pairwise comparisons
revealed no differences between vehicle groups on inactive lever presses, apart from S+ at the 7
mg/ml concentration, p=.007 (Fig. 4B).
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Figure 4: Caffeinated vehicles containing saccharin increase self-administration at multiple
concentrations. Figure A illustrates the final two day average reinforcers earned across
concentrations of caffeine. A 3 x 4 Repeated Measures ANOVA revealed significant a main
effect of Vehicle and interaction of Vehicle x Concentration approaching significance, p=.063,
on reinforcers earned. Figure B illustrates final two day averages of active and inactive lever
presses across concentrations of caffeine. A 3 x 4 Repeated Measures ANOVA revealed
significant main effect of Vehicle on active and inactive lever presses, p’s<.05. Asterisks (*)
denote significant differences of active lever presses and reinforcers earned between the S+/DS+
and vehicle controls, p’s<.05. The hash mark (#) denotes a significant increase in inactive lever
presses for the S+ group compared to water control, p’s<.05.
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Pavlovian Conditioned Approach
Acquisition
PCAI. Caffeine dose-dependently increased sign-tracking (approach to the CS) and
reduced goal-tracking (approach to the location of US delivery) in the Pavlovian conditioned
approach (PCA) paradigm. Figure 5 illustrates the average PCA index (PCAI) across
conditioning sessions for rats assigned to the 0 (n=14), 10 (n=14), and 25 (n=13) mg/kg caffeine
groups. The 10 and 25 mg/kg caffeine doses increased PCAI compared to saline controls (0
mg/kg) and the bias toward sign-tracking increased across conditioning sessions.
This was supported by two-way (Dose x
0.6

Session) ANOVA with significant main
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significance, F(12,324)=1.544, p=.107.
Dunnett's test was used to further assess
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Figure 5: Caffeine increases PCAI when compared
to a saline control group. A Mixed ANOVA revealed
a main effect for Dose and Session on PCAI,
p's<.001. A Dunnett's post hoc analysis revealed
saline controls had significantly lower PCAI than
subjects treated with 10 mg/kg caffeine and 25
mg/kg caffeine bolus doses prior to the start of each
session, p's≤.001. Positive scores indicate a tendency
to be attracted to the lever during CS presentations.
Negative scores indicate a tendency to emit more
behavior towards the receptacle during CS
presentations.

p's≤.001. While the PCAI is a good
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indicator of behavior ‘topography’ during CS presentations, the scores are not sensitive to
acquisition of conditioned responding. For example, a rat that does not acquire an association
and approaches neither the CS nor the US during a test session will receive a score of 0.
Similarly, a rat who equivalently allocates large amounts of behavior to the sign and goal (in
terms of timing, probability, and frequency) will have a PCAI of 0. For this reason, it is
imperative to analyze the individual components that comprise the PCAI in order to get a clearer
picture of how caffeine dose affects Pavlovian conditioning.
Latency analyses. The Latency score is the subtraction of total Goal latency during CS
presentation from total Sign latency during CS presentation. This composite score reveals the
relative speed with which the subject approaches the sign or the goal. A Mixed ANOVA yielded
significant main effects for Session, F(6,342)=23.781, p<.001, Dose, F(2,57)=41.75, p<.001,
and an interaction of Session x Dose, F(12,342)=2.35, p=.007, on Latency Difference score. As
seen in Figure 6A, the 0 mg/kg group, M=23.13, SEM=5.453, has significantly lower Latency
Difference scores compared to 25 mg/kg groups, M=106.425, SEM=7.562, p<.001, but not quite
the 10 mg/kg group, M=37.632, SEM=5.813, p=.135, thus indicating they learned the
relationship between CS and US presentations, as well as a preference to goal-track during CS
presentations. Individual analyses of Sign and Goal latency scores are necessary to understand if
group averages are the result of approach solely to the receptacle and lever or approaching both
with a slight preference to approach the sign or goal first.
Low Sign Latency scores indicate rats are quick to approach the CS when it is presented.
A Mixed ANOVA yielded significant main effects for Session, F(6,342)=, p<.001, Dose,
F(2,57)=13.264, p<.001, and interaction of Session x Dose, F(12,342)=2.186, p<.05, on Sign
Latency score (Fig. 6B). A Dunnett's test to further assess the main effect of Dose revealed that
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Figure 6: Caffeine exhibits a biphasic effect on latency to approach a conditioned stimulus.
Figure A illustrates the Latency Score used to determine PCAI Score. Rats pretreated with 25
mg/kg caffeine had significantly higher Latency Scores than saline controls across conditioning
sessions, p<.001. Figure B illustrates that rats in the 10 mg/kg group were significantly quicker
to approach the sign than the 0 mg/kg group, p<.001. Rats in the 25 mg/kg group were not
significantly different than the 0 mg/kg group in sign latency, p=.194. Figure C illustrates that
rats in the 0 mg/kg group were quicker to approach the receptacle during the CS presentation
than the 25 mg/kg group, p<.001, but no different than rats in the 10 mg/kg group. Taken
together, these figures illustrate rats given a moderate dose of caffeine were quicker to sign-track
than other groups, but still learned the contingency between CS presentations and the following
US presentations. Rats given a high dose of caffeine did not appear motivated to approach the
sign or goal during CS presentations.
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10 mg/kg, M=7.912, SEM=0.522, p=.001, but not 25 mg/kg, M=12.015, SEM=0.679, p=.194,
had significantly lower Sign Latency scores than the 0 mg/kg group, M=10.649, SEM=0.489. In
other words, rats pretreated with 10 mg/kg caffeine were quicker to approach the lever during CS
presentation. Rats in the 25 mg/kg group were no different from the 0 mg/kg group, indicating
weak or no motivation to approach the lever during CS presentation.
Low Goal Latency scores indicate rats are quick to approach the receptacle when the CS
is presented. A Mixed ANOVA yielded significant main effects for Session, F(6,342)=31.239,
p<.001, Dose, F(2,57)=51.846, p<.001, and the interaction of Session x Dose, F(12,342)=3.568,
p<.001, on Goal Latency score (Fig. 6C). Rats in all groups lowered total Goal Latency score
across sessions, indicating learning the contingency between CS presentation and sucrose
reward. However, the time it took to first approach the receptacle was retarded by caffeine in a
dose-dependent manner. A Dunnett's test to further assess the main effect of Dose revealed that
25 mg/kg, M=10.643, SEM=0.473, p<.001, and 10 mg/kg, M=6.283, SEM=0.363, p=.006, had
significantly higher Goal latency scores compared to the 0 mg/kg group, M=4.741, SEM=0.341.
Probability difference score. The Probability difference score [P(sign) - P(goal)] is the
difference in probability of entry into the dipper well (P (goal)) subtracted from the probability
of contacting the lever (P(sign)). Each CS trial results in a 1 or 0 for sign or goal probability if
the rat approaches the lever, receptacle, or not. For example, if a rat contacts the lever in each of
the 15 CS trials, the sum of each trial is 15 which is then divided by 15 for a P(sign) of 1. Once
the P(goal) is taken and subtracted from P(sign) the outcome is a number ranging from -1 - 1.
Low scores represent tendency of a rat to solely goal-track during CS exposure and high scores
represent tendency of a rat to solely sign-track during CS exposure. A Mixed ANOVA yielded a
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significant main effect for Session, F(6,342)=4.500, p<.001 (Fig. 7A). No Dose, F(2,57)=2.312,
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Figure 7: Moderate doses of caffeine increase probability to approach a conditioned stimulus.
Figure A illustrates average Probability Difference Scores across all sessions of conditioning. A
Mixed ANOVA revealed a main effect for Session, p<.001, but not Dose, p=.108 on Probability
Difference Score. Figure B illustrates average probability of sign contacts across sessions.
Dunnett’s post hoc analysis revealed 10 mg/kg, p=.002, but not 25 mg/kg groups, p=.288, had
significantly higher P(sign) scores. Zero and 25 mg/kg groups did not approach the sign in more
than half of CS trials each session. Rats in the 10 mg/kg group were systematically more likely to
contact the lever across sessions, with the highest P(Sign) score during the final session of
conditioning. Figure C illustrates average probability of receptacle entries during conditioning.
Dunnett’s post hoc analysis revealed saline controls were significantly more likely to enter the
receptacle than rats treated with 25 mg/kg caffeine, p<.001, but no different than rats pretreated
with 10 mg/kg caffeine, p=.091.
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Sign probability scores (P(sign)) range from 0 to 1 indicate how often an animal
contacted the lever during CS presentation for each trial. A score of 0 indicates a rat did not
contact the lever during any CS presentation, and a score of 1 indicates a rat contacted the lever
during every CS presentation. A Mixed ANOVA yielded significant main effects for Session,
F(6,342)=25.922, p<.001, and Dose, F(2,57)=10.84, p<.001, but no interaction between Session
and Dose, F(12,342)=1.279, p=.229, was detected (Fig.7B). A Dunnett's test to further assess the
main effect of Dose revealed 10 mg/kg, M=0.657, SEM=0.045, had significantly higher P(sign)
scores (p=.002) than the 0 mg/kg group, M=0.438, SEM=0.043, but there was no difference
between 0 mg/kg and 25 mg/kg groups, M=0.336, SEM=0.059, p=.288. As seen in Figure 7B,
rats pretreated with 10 mg/kg caffeine were more likely than the 0 mg/kg group to contact the
lever during each sessions of conditioning. Although all groups increased lever contacts across
sessions, 0 mg/kg and 25 mg/kg groups never contacted the lever in half of CS presentations
during any one session.
Goal probability scores (P(goal)) range from 0 to 1 indicating how often a rat entered the
receptacle during CS presentation for each trial. A Mixed ANOVA yielded significant main
effects for Session, F(6,342)=40.942, p<.001, Dose, F(2,57)=49.861, p<.001, and a Session x
Dose interaction, F(12,342)=4.172, p<.001), on P(goal) (Fig. 7C). A Dunnett's test to further
assess the main effect of Dose revealed that the 0 mg/kg group, M=0.879, SEM=0.026, had
higher P(goal) scores than the 25 mg/kg group, M=0.446, SEM=0.036, p<.001, but were no
different from 10 mg/kg group, M=0.803, SEM=0.028, p=.091. As seen in Figure 7C, 0 mg/kg
and 10 mg/kg groups were motivated to obtain sucrose with receptacle entries in nearly every CS
presentation trial from session 3-7. The 25 mg/kg group learned to approach the receptacle
during CS presentations over multiple sessions but never exceeded more than 75% of trials. A
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steady but slowed learning curve, in combination with a limit of 0.7 P(goal) indicates that the 25
mg/kg dose reduced motivation to obtain sucrose.
Response bias score. The response bias score reflects the difference between lever
contacts and receptacle entries during each CS trial [(total lever contacts - total receptacle
entries)/(total lever contacts + total receptacle entries)]. Response bias scores range from -1 - 1
where -1 scores indicate only goal-tracking behavior and +1 indicating only sign-tracking
behavior. A Mixed ANOVA yielded significant main effects for Session, F(6,342)=6.673,
p<.001, and Dose, F(2,57)=12.874, p<.001, on response bias score (Fig. 8A). No Session x
Dose, F(12,342)=0.912, p=.535, was detected. A Dunnett's test to further assess the main effect
of Dose revealed that 25 mg/kg, M=0.159, SEM=0.102, p<.001, and 10 mg/kg, M=0.176,
SEM=0.079, p<.001, had significantly higher Response Bias scores compared to 0 mg/kg, M=0.32, SEM=0.074. The Response Bias Score can make it hard to discern the rates of sign- and
goal-tracking sign-tracking over the entire session. Hypothetically, rats that touch the lever and
enter the receptacle the same amount of times over the session can have the same Response Bias
Score regardless of the total contacts and receptacle entries during the session. For this reason, it
is important to look at the Sign and Goal Bias scores alone to better understand overall rates of
responding.
Sign Bias Score is the sum of lever contacts during CS presentations within a session.
Rats that are more likely to sign-track are expected to have higher total lever contacts over a
session. A Mixed ANOVA yielded significant main effects for Session, F(6,342)=6.787,
p<.001), Dose, F(2,57)=10.96, p<.001, and a Session x Dose interaction, F(12,342)=1.831,
p=.042, on CS contacts (Fig. 8B). A Dunnett's test to further assess the main effect of Dose
revealed that 0 mg/kg, M=35.669, SEM=6.925, rats had significantly lower lever contacts than
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Figure 8: A moderate dose of caffeine elicits bias to a conditioned stimulus. A Mixed ANOVA
revealed a main effect for Dose and Session on Response Bias Score, p's<.001. A Dunnett's post
hoc analysis revealed saline controls had significantly lower Response Bias Scores than subjects
treated with 10 mg/kg caffeine and 25 mg/kg caffeine bolus doses prior to the start of each
session, p's≤.001. Figure B illustrates average lever contacts during CS trials across sessions.
Dunnett’s post hoc analysis revealed 10 mg/kg, p=.001, but not 25 mg/kg, p=.537, had
significantly more lever contacts. Figure C illustrates average session receptacle entries during
conditioning. Dunnett’s post hoc analysis revealed saline controls had significantly more
receptacle entries than rats treated with 10 and 25 mg/kg caffeine, p's≤.001. Taken together,
these graphs illustrate caffeine’s biphasic effects on sign- and goal-tracking behavior. While 25
mg/kg was not different than 10 mg/kg on Response Bias Scores, the Sign and Goal Bias scores
reveal that 25 mg/kg reduced responding towards the sign and goal. These graphs illustrate that a
high dose of caffeine may impair motor behavior or reduce motivation to approach a US and the
CS. In contrast, 10 mg/kg elicited higher rates of sign and goal-tracking, revealing that rats in
this group were motivated to approach both the US and CS.

56

10 mg/kg, M=74.221, SEM=7.382, p=.001, but was no different from 25 mg/kg, M=24.176,
SEM=9.603, p=.537. As seen in Figure 8B, the 10 mg/kg group began with a higher tendency to
sign-track which was perpetuated over multiple sessions. Zero and 25 mg/kg groups maintained
relatively low rates of CS contacts across sessions.
Goal Bias Score is the sum of receptacle entries during CS presentations in a session.
Rats that are more likely to goal-track are expected to have higher total receptacle entries over a
session. A Mixed ANOVA yielded significant main effects for Session, F(6,342)=20.159,
p<.001, Dose, F(2,57)=29.608, p<0.001, and a Session x Dose interaction, F(12,342)=4.243,
p<.001, on receptacle entries (Fig. 8C). A Dunnett's test to further assess the main effect of
Dose revealed the 0 mg/kg group, M=58.571, SEM=3.411, had significantly more receptacle
entries than 10 mg/kg, M=36.247, SEM=3.636, p<.001, and 25 mg/kg groups, M=14.67,
SEM=4.731, p<.001. As seen in Figure 8C, caffeine retarded receptacle entries across sessions in
a dose-dependent manner. Figure 8B and 8C displaying both Sign and Goal Bias Scores illustrate
how a high dose of caffeine can disrupt the association between the CS and sucrose
presentations, as well as reduce the motivation to obtain sucrose.
Microdialysis Session
PCAI. A One Way ANOVA yielded a non-significant main effect for Dose, p>.05, on
PCAI during CS presentations (Fig. 9A). Only CS exposed rats were included in the analysis
since PCAI could not be calculated for rats that could not sign-track due to the lack of CS
presentations.
CS contacts. A 2 x 3 (CS Group x Dose) Two Way ANOVA only found a significant
effect of CS Group on CS Contacts, p<.05 (Fig. 9B). There was no significant main effect for
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Dose or a significant interaction of Dose x CS Group, p’s>.05. Not surprisingly, CS
presentations caused more sign-tracking behavior. When controlling for CS presentations,
caffeine dose did not affect sign-tracking behavior when CS-US pairings were extinguished.
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Figure 9: Exposure to a conditioned stimulus evokes sign- and goal-tracking behavior during
CS-US extinction. Figure A represents difference in PCAI between CS and No-CS groups during
Microdialysis. Filled symbols represent groups who were exposed to CS presentations alone.
Open symbols represent groups that received no CS exposure. A One Way ANOVA did not
detect an effect of dose on PCAI, p>.05. Figure B represents average CS contacts during the CS
exposure segment (1 hr) of session. A 2 x 3 (CS Group x Dose) ANOVA revealed a significant
effect of CS Group on CS Contacts, p<.05. Figure C represents average Goal Entry Elevation
Score during CS exposure segment (1 hr) of the session. A 2 x 3 ANOVA revealed a significant
effect of CS Group on goal entry elevation score, p<.05
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Goal entry elevation score. A 2 x 3 (CS Group x Dose) Two Way ANOVA revealed a
significant effect of CS Group on goal entry elevation score, p<.05 (Fig. 9C). There was no
significant main effect for Dose or a significant interaction of Dose x CS Group, p’s>.05. As
expected, CS presentations caused more goal-tracking behavior compared to no CS
presentations. However, caffeine did not affect goal-tracking behavior when CS-US pairings
were extinguished.
Dopamine dialysate. Caffeine pretreatment increased extracellular dopamine, but only in
rats that were tested with the CS. This was confirmed by analyses of Area Under the Curve
(AUC) calculated from percent change in DA over 2 sample intervals – samples that were in the
brain during the test phase (Test Interval, samples 6-8) and samples that were in the brain during
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Figure 10: A moderate dose of caffeine enhances sensitivity of accumbal dopamine in response
to a conditioned stimulus. Figures A and B represents group average of the area under the curve
derived from percent change from baseline dopamine efflux for each sample collected during the
Microdialysis session. Figure A represents the group averages for rats in the No-CS groups.
Figure B represents the group average for rats in the CS groups. The Test interval represents the
average of the three samples collected during CS test exposure (samples 6-8). The Post-Test
intervals represent the average of the three samples collected after CS test exposure (samples 911). The asterisk (*) represent a significant increase in AUC during the Post-Test compared to
the Test interval for rats exposed to 10 mg/kg caffeine, p<.05.
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the 1 h post test period (Post Test Interval, samples 9-11). A 2 x 3 (Interval x Dose) ANOVA on
groups exposed to the CS revealed significant main effects of Interval, F(1,11)=10.61, p=.02,
and Dose, F(2,11)=4.024, p=.048, as well as an Interval x Dose interaction approaching
significance, F(2,11)=2.68, p=.11 (Fig. 10B). Because there were 3 levels of Dose and a main
effect of Interval, pairwise comparisons using Bonferroni’s correction examined the main effect
of Dose during each interval. The 10 mg/kg group, M=322, SEM=76.1, showed a significant
increase in extracellular DA, relative to the 0 mg/kg group during the Post Test interval,
M=100.9, SEM=44.4, p<.05. There were no differences in accumbal dopamine between the 0
mg/kg group and the 25 mg/kg group during the Test and Post Test intervals, p’s>.05.
The 2 x 3 (Interval x Dose) ANOVA on groups not exposed to the CS revealed a
significant effect of Interval, F(1,18)=6.274, p=.02, a main effect of Dose approaching
significance, F(2,18)=3.248, p=.0625, and no Interval x Dose interaction, p=.79, on AUC (Fig.
10A). Pairwise contrasts using Bonferroni’s correction did not reveal any significant differences
between doses during the Test and Post Test intervals, p’s>.05.
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CHAPTER 4
DISCUSSION
The effects of caffeine on appetitive behaviors are complex. Although it is the most
consumed psychoactive substance in the world, it is not a primary reinforcer in preclinical
models. This is notable because humans clearly self-administer the drug for the psychoactive
effect but no other species will. However, most preclinical models fail to account for the
complexity of caffeine self-administration by humans – consumption of the drug in a vehicle
containing reinforcing gustatory stimuli. Despite these shortcomings, preclinical research is rife
with evidence that caffeine alters motivation for other reinforcers. Caffeine systematically
increase behaviors associated with a diverse array of primary rewards including cocaine,
amphetamine, sucrose, and visual stimuli (Cauli et al., 2003; Green & Schenk, 2002; Sheppard et
al., 2012). As a result, caffeine has been identified as a ‘reinforcement enhancer’ and this
characteristic may play an important role in caffeine use (Sheppard et al., 2012; Sweeney et al.,
2016).
Delivery of oral saccharin with intravenous caffeine infusions promoted robust
acquisition and maintenance of caffeine self-administration compared to caffeine infusions
alone. The peak caffeine doses (0.5-1 mg/kg/infusion) produced approximately three times the
amount of active lever presses when they were delivered with saccharin, relative to saccharin
alone. Delivering caffeine in an oral vehicle also supported the necessity a primary reinforcer.
Rates of caffeine self-administration were highest for groups responding for solutions containing
saccharin and low-to-moderate concentrations of caffeine (S+, DS+) when compared to groups
receiving solutions containing saccharin alone (S-, DS-), caffeine alone (W+), or neither (W-).
Differences between groups for active lever presses and reinforcers earned were observed at a
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concentration of 2.5 mg/ml of caffeine. All concentration of caffeine promoted significantly
higher responding for saccharin solutions than water alone, with the exception of 7.0 mg/ml.
Caffeine's ability to alter associations between cues and the rewards they predict was
examined using a PCA paradigm. A moderate dose of caffeine (10 mg/kg) elicited more signtracking across acquisition sessions, as evidenced by faster approach to the CS, higher
probability of contacting the CS, and more interaction (contacts) with the CS. Rats who received
placebo pretreatments (0 mg/kg) exhibited more ‘goal-tracking’ relative to the 10 mg/kg caffeine
pretreated rats. These rats were quicker to approach the sucrose receptacle and entered the
receptacle more often when the CS was presented. A high dose of caffeine (25 mg/kg) appeared
to inhibit acquisition of conditioned responding as both sign- and goal-tracking were reduced
compared to the 0 and 10 mg/kg caffeine. Although their PCAI did not differ from the 10 mg/kg
caffeine group, rats receiving 25 mg/kg were less likely to approach the sign, goal, and had
larger latencies to approach the CS and receptacle. Lastly, 10 mg/kg caffeine increased
extracellular dopamine evoked by CS presentations during in vivo microdialysis tests. No
increase in dopamine efflux was observed at 0 and 25 mg/kg caffeine doses for rats exposed to
the CS. These findings are consistent with our hypothesis that caffeine increases the salience of
incentives by enhancing or sensitizing the NAc dopamine response to incentive stimuli.
Caffeine Self-Administration
This is the first investigation examining the role of contingently paired primary
reinforcers and caffeine in the acquisition and maintenance of caffeine self-administration. The
present studies demonstrate caffeine self-administration is caused by the adventitious pairing of
the drug with response-contingent vehicle reinforcers. In other words, caffeine does not have to
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function as a primary reinforcer to be self-administered, but can promote self-administration by
the enhancing the reinforcing effects of non-drug rewards (Sheppard et al., 2012), such as those
included in the caffeine vehicle (present studies). It is surprising that no primary reinforcing
effect of a drug is necessary to potentiate self-administration to high levels. Instead, the drug
strengthens operant behavior by increasing the motivation to obtain saccharin. This matches the
majority of human caffeine consumption where the drug is consumed in a beverage, typically
coffee and energy drinks, which has created a subset of habitual users (Reissig, Strain, &
Griffiths, 2009). One question that arises from this hypothesis is mechanistic - how does caffeine
promote vehicle reinforcement without an established primary reinforcing effect? The selfadministration data from these studies suggest this effect is achieved through the
pharmacokinetic actions of caffeine. The pharmacokinetic effects of caffeine, specifically its
long lifespan, make it more suited to a moderating role on non-drug reinforcement.
Pharmacokinetics of caffeine
Traditional 'primary reinforcement' views of drug self-administration posit that a timesensitive pairing between a well-defined operant response (e.g., pressing a lever) and the
pharmacological effect of the drug is necessary for associative learning (Wise, 1987; Wise &
Koob, 2014). This theory emphasizes the speed at which the drug reaches its targeted site of
action in the brain is important to drug reinforcement and abuse liability (Bouayad-Gervais,
Minogianis, Lévesque, & Samaha, 2014). However, drugs which are consumed orally, namely
alcohol and caffeine, have a significant delay between initial consumption and the
pharmacological effect (Latini, Tognoni, Young, & Garattini, 1984; Sher, 1985). Delays between
consumption and subjective drug effect make the pharmacological effects of the drug more
contextual and less discrete. Instead, the immediacy of the chemosensory effects of the beverage
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is likely reinforcing the operant response while the drug functions as a contextual stimulus or
moderator. On one hand this explains most human caffeine consumption and the findings from
Experiment 2, yet it does not explain why intravenous caffeine is not self-administered alone in
Experiment 1 or previous literature (Atkinson & Enslen, 1976; Griffiths et al., 1979).
Intravenous caffeine rapidly reaches the brain and, therefore, is presumably associated
with the operant response (Wise & Koob, 2014). Unlike other intravenously self-administered
drugs, caffeine is eliminated slowly, with a half-life between 60-90 minutes in the rat (Latini et
al., 1980; Smith, Ma, & Lau, 1999). This lengthy availability of caffeine at targeted receptor sites
may make the pharmacological effects more contextual and less discrete than the saccharin
presented with each infusion. Intravenous caffeine infusions are only made salient by the drug's
interoceptive cues and a slight auditory cue of the syringe pump. On the other hand, saccharin
presentations are accompanied by the auditory cue of the dipper, visual cue of dipper movement
and eventual sensory cues of the flavor during consumption. Therefore, it is reasonable to
assume lever presses are readily associated with presentations of saccharin and the
accompanying, salient stimuli. As sessions progress, the association between the lever and
saccharin are strengthened by multiple pairings, with caffeine moderating the association. Rapid
acquisition of oral and intravenous self-administration provides compelling evidence for this.
However, differences between the intravenous dose-response curve and the oral concentration
curve demand further scrutiny.
Comparing-Contrasting Intravenous and Oral Caffeine Self-Administration
Experiment 1 provided proof-of-concept for an animal model of caffeine selfadministration. Experiment 2 added ecological validity to this paradigm by modeling typical
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human caffeine use. A preclinical model of oral caffeine self-administration allows researchers
to better understand the factors that influence human caffeine use. Factors such as taste, smell,
intestinal drug absorption and corresponding caffeine distribution are all potentially important
factors that are unique to an oral self-administration. For instance, caffeine has a potent bitter
taste which may negatively influence drug consumption. Despite using a concentration larger
than most commercially available caffeinated beverages, rats reliably acquired high rates of
responding for caffeinated vehicles containing saccharin. Furthermore, the use of decaffeinated
coffee as a masking agent for the bitter taste of caffeine was unnecessary since S+ and DS+
groups acquired self-administration at similar rates. Rats in these groups responded at higher
rates across acquisition and concentration exploration. Continued use of caffeine despite the
negative consequence of bitter flavor offers compelling evidence that this preclinical model is a
useful tool for investigation of caffeine abuse and dependence. Despite validating the
intravenous model of caffeine self-administration, Experiment 2 revealed significant differences
in the relationship between caffeine dose or, concentration, and the rate of reinforcers earned.
The dose response curve for intravenous caffeine self-administration illustrate the
boundaries to which caffeine is effective at promoting self-administration when paired with
saccharin compared to saccharin and caffeine control groups. Intravenous infusions of .125
mg/kg are too low to achieve a psychoactive dose and only a few infusions of 4 mg/kg are
needed to achieve satiation. The concentration curve for oral self-administration does not provide
similar evidence for the lower and upper concentrations of caffeine necessary to reduce
motivation to levels equivalent to control groups. In addition to route of administration, the
ability to precisely control caffeine dose could be responsible for these differences. In
Experiment 2 a liquid dipper delivered 0.1 ml of the assigned caffeinated solution upon meeting
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the ratio requirement. The dipper remained available for the rat to freely consume the solution
until the next response ratio was met. Free access to solutions allowed rats to titrate their caffeine
intake in a manner similar to human caffeine consumption. Hypothetically, rats could be
achieving similar doses of caffeine with different concentrated solutions by adjusting how often
and how much solution they consume. This ability to precisely control caffeine dose was not
available in our intravenous model. Rats could adjust their dose only at the assigned increment of
infusion. A quick elevation of dose in which the drug rapidly reaches the targeted receptor site
within the CNS could explain why infusions of 4 mg/kg produced low levels of responding.
These stark differences between groups receiving saccharin with 4.0 mg/kg intravenous caffeine
or 7.0 mg/ml oral caffeine illustrate the importance for an ecologically valid model of human
caffeine use. By mimicking human caffeine use, this model integrates factors that may have been
previously overlooked by researchers such as precise control of caffeine dose. Animal models of
oral caffeine self-administration will prove to be a useful tool for future research investigating
the significant factors that influence initiation and maintenance of caffeine use.
Caffeine and Incentive Salience
Experiments 1 and 2 provide empirical evidence that tandem presentations of caffeine
with reinforcing gustatory stimuli perpetuate self-administration. These studies explain why
caffeine is so readily used and abused, but they do not explain how caffeine increases motivation
to obtain reinforcers and perpetuate caffeine use. Based on prior research we know caffeine
enhances operant responding for drug and non-drug reinforcers (unconditioned reinforcers), as
well as establish non-drug stimuli as conditioned reinforcers (Yeomans, et al., 2005; Yeomans et
al., 2007). In other words, caffeine consumption reflects a complex interaction between drug and
non-drug stimuli (Fedorchak, Mesita, Plater, & Brougham, 2002; Myers & Izbicki, 2006;
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Yeomans, Javaherian, Tovey, & Stafford, 2005). However, it is unclear whether caffeine
interacts with the motivational properties of the reward, reward-associated cues, or both.
The PCA paradigm investigates the incentive salience of rewards and associated cues by
quantifying approach behavior evoked by both stimuli. In Experiment 3 we discovered a
moderate dose of caffeine enhanced sign-tracking behavior. Importantly, 10 mg/kg caffeine
reduced goal tracking (approach to the sucrose receptacle, Figure 8C) but increased sign-tracking
(contacts with the lever, Figure 8B) across testing sessions. The more the CS predicted the
reward, the more that caffeine enhanced the motivational properties of that CS. In other words,
caffeine enhanced the incentive salience of the CS with each CS-US pairing and, in turn, elicited
more approach behavior.
Another important finding is the effect of the high dose of caffeine on conditioned
approach behavior. Surprisingly, 25 mg/kg of caffeine did not enhance incentive salience of the
CS more than the 10 mg/kg dose. Instead, the high dose of caffeine inhibited sign and goaltracking behavior compared to saline and 10 mg/kg caffeine. This high dose was too low to
impair motor behavior, but some human research may explain why 25 mg/kg caffeine impaired
learning. At high doses caffeine impairs performance in working memory tasks in human
volunteers (Kaplan et al., 1997). This may explain why rats receiving a high dose of caffeine
were never more than 50% likely to approach the sign during CS trials in the final acquisition
sessions. Alternatively, the psychomotor stimulant effects of caffeine could have reduced the
likelihood that rats were near the lever and light during acquisition of conditioned approach.
However, this explanation seems unlikely because there was no ambient light in the chamber
during testing – the illumination of the stimulus light above the lever would have been the only
light in the apparatus during CS presentations, and the rats should have been able to detect it
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from anywhere in the chamber. Finally, the anorectic effects of caffeine may have reduced the
impact of the sucrose US. This seems unlikely because small quantities (0.1 ml), with
presumably mild post-ingestive effects, were delivered on each trial. Future research is necessary
to confirm the behavioral impairment observed with 25 mg/kg caffeine pretreatments.
The enhanced salience of CSs by a moderate dose of caffeine provides an explanatory
framework for how the drug functions as a ‘reinforcement enhancer’ even though perception of
the reward (sucrose) is apparently unchanged. Incentive sensitization is a common feature of
popular drugs of abuse. Common illicit substances, such as cocaine and amphetamine, perpetuate
substance use by inducing cravings which are triggered by the cues that commonly predict drug
use (Robinson & Berridge, 1993). Through multiple pairings with the drug, these cues acquire
motivational properties. It is theorized that the mesolimbic dopamine system, the final common
pathway for drugs of abuse, becomes sensitive to these drug-predictive cues and is responsible
for elicited drug cravings (Robinson & Berridge, 1993). Experiment 3 provides evidence that
caffeine enhances approach to cues that predict reward delivery. For example, this may explain
why habitual caffeine consumers have beverage preferences (Reissig et al., 2009). Tastes and
smells that were once novel, such as coffee or energy drink flavors, now are powerful reinforcers
that promote coffee consumption because of previous pairings with sugar, cream, or even social
activity.
Caffeine Enhances CS-Elicited Dopamine Release in the Nucleus Accumbens
Past findings indicate that sensitivity of dopamine efflux is responsible for the attribution
of incentive salience (Flagel & Robinson, 2017). In support of previous research, our results
suggest a moderate dose of caffeine enhances the ability of a reward-predictive cue to elicit
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dopamine in the NAc. Aggregate increases in dopamine were only seen after repeated CS
exposure for rats treated with an acute dose of 10 mg/kg caffeine. Two critical comparisons were
necessary to ensure that dopamine release was not caused by the CS or caffeine alone. First, a
saline group exposed to the CS did not exhibit changes in dopamine during CS exposure (Test
Interval) or afterwards (Post Test Interval). The CS was not enough to elicit increases in
accumbal dopamine efflux during either interval. Next, a 10 mg/kg caffeine group with no CS
exposure did not change dopamine efflux during either interval. The moderate dose of caffeine
was not enough to elicit increases in accumbal dopamine efflux. Instead, only the 10 mg/kg
group exposed to the CS exhibited increases in dopamine efflux during the Post Test Interval.
These findings correlate with the behavioral data from PCA acquisition and provide further
evidence that NAc dopamine mediates incentive salience.
Previous research using fast scan cyclic voltammetry (FSCV) to record NAc dopamine in
real time suggest reward-predictive cues elicit immediate, phasic bursts of dopaminergic activity
(Sunsay & Rebec, 2014). Despite these findings, we did not observe significant changes in
dopamine efflux until the hour following repeated CS exposure. These seemingly opposing
findings can be attributed to differences in methods. First, microdialysis provides low temporal
resolution of dopamine efflux. A 20 minute temporal resolution limits the acuity to which we can
observe significant changes in dopamine. In other words, low resolution does not allow us to
observe changes in dopamine efflux during each CS trial. Instead, aggregate changes in
surrounding neurons are necessary to detect differences in dopamine efflux. Noticeable changes
may take time for a drug that indirectly promotes dopamine efflux like caffeine. Caffeine does
not induce phasic dopamine response alone and may promote tonic rises in dopamine in the

69

reward pathway during the drug's long half-life. Additionally, the removal of sucrose after CS
presentations could have affected the time course of dopamine elevation.
Pavlovian extinction between a CS and US decreases the amplitude of dopamine signal
elicited by the CS (Sunsay & Rebec, 2014). For that reason, it is likely that CS-elicited dopamine
decreased with each exposure to the CS in our study. Reduction of dopamine signal amplitude
may explain why we were not able to observe dopamine changes during the Test interval for the
saline-CS and 10 mg/kg-CS groups. While using an extinction procedure may have reduced
caffeine's ability to promote dopamine activation elicited by the CS, sucrose presentations may
have influenced dopamine efflux in all groups and masked any differences we could observe
between groups. Taken together, the low temporal resolution of microdialysis combined with
CS-US extinction may explain the delayed dopamine efflux after CS exposure in the 10 mg/kg
caffeine group. These data indicate that small elevations in dopamine efflux caused by CS
exposure, and perpetuated by caffeine, lead to aggregate elevations in tonic dopamine efflux.
In addition to group differences between saline and 10 mg/kg caffeine groups, dopamine
recordings from the 25 mg/kg caffeine groups help explain the disruption in associative learning
seen during acquisition. Groups exposed to a high dose of caffeine did not exhibit any overall
changes in dopamine between the Test and Post Test Intervals. The inhibition of dopamine
sensitivity to CS exposure provides further evidence that a high dose of caffeine inhibits
learning. As previously discussed, high doses of caffeine inhibit working memory performance
in human volunteers. Our data suggest that disrupted learning caused by high doses of caffeine
may be caused by a disruption of the mesolimbic system’s ability to encode associations between
stimuli. This may inhibit word recall in humans or inhibit incentive attribution to cues predictive
of reward in rodents.
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Future Directions
Caffeine Self-Administration
Experiments 1 and 2 provided the proof-of-concept and general parameters for a robust
preclinical model of caffeine self-administration. Experiment 1 explored the range of doses at
which intravenous caffeine promoted self-administration when paired with the presentation of
liquid saccharin. Experiment 2 validated the preclinical model while establishing the parameters
at which caffeine concentration promoted oral self-administration for vehicles containing
saccharin and caffeine. Due to the novelty of this paradigm, many questions regarding factors
influencing caffeine self-administration went unanswered. One important manipulation for future
research will be the removal of caffeine. As we saw in Experiment 3 and previous research,
caffeine alters incentive salience of reward-related cues. In accordance with our sign-tracking
data, it is likely that previous caffeine exposure enhances the incentive salience of the active
lever and would likely promote continued approach despite removal of contingent caffeine.
Researchers could explore the degree to which groups self-administering caffeine will continue
to lever press for saccharin once the drug is removed. This alteration in reward outcome could be
a useful indicator for preclinical researchers to explore abuse liability. Continued elevation in
lever pressing could be interpreted as sustained drug-seeking despite removal of caffeine.
A second manipulation for future researchers could be the alteration of caffeine’s ability
to antagonize adenosine receptor sites. Caffeine antagonizes adenosine A1 and A2A receptors via
competitive binding and indirectly enhances constitutive dopamine receptor activity (Ferré,
2008). We have hypothesized that this indirect enhancement of dopamine efflux is responsible
for caffeine self-administration. To confirm this hypothesis, future research could systematically
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explore the relationship between selective adenosine receptor antagonism and caffeine selfadministration. In addition, adenosine agonists and adenosine kinase inhibitors could be used to
understand how endogenous adenosine affects caffeine self-administration. Hypothetically,
enhanced adenosine could blunt the effect of caffeine by displacing it from the A1 and A2A
receptor site. If this were true, adenosine agonists could potentially shift the dose-response curve
to the right or reduce the amplitude of the curve for caffeine self-administration behavior.
Pavlovian Conditioned Approach
Experiment 3 confirmed that a moderate dose of caffeine enhanced the incentive salience
of a reward-predictive cue. A dose of 10 mg/kg caffeine enhanced sign-tracking behavior that
was not seen at the 0 and 25 mg/kg dose. While we were able to make some general conclusions,
further exploration is needed to understand the dose parameters at which caffeine enhances
incentive salience, understand why 25 mg/kg reduce performance in this paradigm, and
understand what the long-term effects are of caffeine on incentive salience. It appears a dose of
25 mg/kg of caffeine is enough to define the upper bound of caffeine's effectiveness to promote
sign-tracking behavior. Nonetheless, our limited dose exploration provides a narrow scope to
understanding the relationship between caffeine and incentive salience at lower doses. It is
possible that lower doses of caffeine can enhance sign-tracking behavior but research exploring
differences in dose between groups of rats is necessary.
There are two possible reasons 25 mg/kg caffeine did not facilitate sign-tracking
behavior: the high dose of caffeine interfered with the ability to learn the association between the
CS and US, or it impaired motor performance. Based on our dopamine data and research on
working memory tasks with human volunteers, it appears that the high dose of caffeine impaired
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the ability to learn the predictive relationship between the CS and US (Kaplan et al., 1997). To
verify this hypothesis, future studies could conduct a 'probe' session after acquisition. During this
'probe' session, rats previously given 25 mg/kg caffeine could be give sham injections with
saline. If caffeine impaired learning, these rats should have conditioned approach behavior
comparable to the first day of acquisition for a saline control group. If caffeine impaired
performance, conditioned approach to the CS during the probe session should be equivalent to
rats assigned to a moderate dose of caffeine.
Another avenue for future research is explorations into the long-term effects of caffeine
on incentive salience. Results from similar research with nicotine show persistent sign-track after
drug removal suggesting nicotine permanently alters incentive motivation (Palmatier et al.,
2012). In other words, once nicotine enhanced the incentive salience of a reward-predictive cue,
the drug was no longer needed for the cue to facilitate conditioned approach. Since caffeine and
nicotine both promote sign-tracking, we hypothesize that sign-tracking would persist following
caffeine removal. Data from habitual users also supports this hypothesis. Habitual consumers of
energy drinks have strong beverage preferences which suggests caffeine may permanently alter
incentive motivation of reward-associated flavors (Reissig et al., 2009). If preclinical researchers
can illustrate the intractable nature of these cues to elicit approach behavior after caffeine
exposure, this could inform clinicians on the importance of caffeine-associated to induce use
after drug cessation.
Dopamine
Microdialysis data from Experiment 3 suggest that caffeine promotes dopamine efflux in
response to conditioned cues. We hypothesize that this alteration in dopamine, while slow, is
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evidence to support the mechanism by which caffeine promotes incentive salience to rewardpredictive cues. Although we can speculate, empirical evidence is needed to better illustrate the
interaction between caffeine, incentive cues, and rewards. For example, we removed sucrose
from microdialysis testing to prevent rises in dopamine occurring across all groups and masking
any smaller magnitude changes caused by caffeine’s interaction with the CS. However, this
precaution is only speculative and future research with CS-US pairings is necessary to confirm
this hypothesis.
The low temporal resolution of dopamine efflux afforded by microdialysis recordings
leaves speculation for the mechanism by which caffeine promotes dopamine in response to the
CS. Large, observable changes in dopamine efflux did not occur until the hour following CS
presentations which suggest that caffeine either has no immediate impact on CS-evoked
dopamine efflux or produces such small changes in dopamine response that more sensitive tools
are necessary. Techniques for brain activity recordings with better temporal resolution could
provide valuable information to understanding the caffeine-CS-US relationship. One technique,
fast scan cyclic voltammetry (FSCV) provides sub-second recordings of transient dopamine
signal at the level of individual or small groups of dopamine-firing neurons. In vivo recordings
using FSCV would allow researchers to determine if caffeine alters the amplitude of dopamine
signal evoked by CS presentations in a PCA paradigm. This data would provide the most
compelling evidence that caffeine mediates dopamine sensitivity to incentive stimuli.
Limitations
The current experiments are the first to establish a robust preclinical model for the
acquisition and maintenance of caffeine self-administration. Tandem delivery of caffeine with
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saccharin, a gustatory reinforcer, enhances motivation to obtain saccharin while perpetuating
caffeine self-administration. We hypothesized that this effect is caused by caffeine’s ability to
enhance incentive salience. While intravenous caffeine self-administration offered the strongest
support for this hypothesis, our interpretations of the oral model are limited. First, we are unable
to determine caffeine dose since rats were not required to drink any or all of the earned solution
in between reinforcer presentations. Analysis of receptacle entries after dipper presentations may
offer better indication of consummatory behavior. Second, a clear and systemic relationship was
observed between oral caffeine dose and inactive lever presses. Although rats receiving
saccharin and caffeine solutions (S+, DS+) were able to distinguish between active and inactive
levers, rats were more likely to press the inactive lever when reinforcers had higher
concentrations of caffeine. As previously discussed, one reason for this could be the method for
session length. Once the ratio requirement was above what rats were willing to work, rats had to
wait thirty minutes before the session would end. This extended session length leaves more time
for rats to explore the chamber and respond on the inactive lever. Definitive session lengths, like
those in Experiment 1, may eliminate this effect.
Dopamine efflux recorded via microdialysis in Experiment 3 increased when rats were
pretreated with a moderate dose of caffeine and exposed to a CS. Unexpectedly, this change in
dopamine was not observed until the final hour of dialysate collection when nothing was
occurring in the operant chamber. In fact, dopamine efflux continued to increase with each
sample collected after CS exposure. While we cannot be sure what caused this late surge in
dopamine, comparisons to our other groups indicate the experiment-administered caffeine and
CS exposure were responsible for this change. Since no sucrose was presented after the CS
during microdialysis, it is possible that CS-US extinction was responsible for a lack of dopamine
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changed observed earlier in the session (Sunsay & Rebec, 2014). Future research using
electrophysiological recording will provide a better understanding of caffeine's influence on
dopamine signal in response to rewards and incentive cues.
Conclusion
The current series of experiments are the first to show reliable and robust caffeine selfadministration in a preclinical paradigm when the drug is delivered in tandem with a gustatory
reinforcer. Moreover, the effects of tandem saccharin-caffeine delivery generalize to both oral
and intravenous models of self-administration. In addition, caffeine enhances incentive salience
of cues that predict rewards and promotes sign-tracking behavior in a pavlovian conditioned
approach paradigm. This promotion of incentive salience and corresponding accumbal dopamine
efflux may explain the acquisition and maintenance of caffeine self-administration. In
combination with research outlining caffeine's reinforcement enhancing properties (Sheppard et
al., 2012), our models of self-administration, pavlovian conditioned approach, and accumbal
dopamine efflux indicate that caffeine may be better described as an 'incentive amplifier' like
nicotine (Bevins & Palmatier, 2004; Palmatier et al., 2013, 2012). These results suggest that
caffeine's incentive amplifying effects may perpetuate self-administration to potentially
dangerous levels when heavy concentrations of the drug are placed in vehicles containing salient
gustatory reinforcers such as coffee and energy drinks. Finally, these studies highlight the need
for additional research to understand caffeine's ability to sensitize the mesolimbic dopamine
system, the 'final common pathway' for the reinforcing effect of abused drugs.
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